Archive for the ‘Genetic Testing’ Category

MarketsandResearch.biz adds a new report titled Global Direct-to-Consumer Genetic Testing (DTC-GT) Market 2020 by Company, Regions, Type and Application, Forecast to 2026 to its online database. The report offers a detailed overview of the factors, the latest market insights with upcoming trends, and breakdown of the products and services. The report presents information on industry trends, top manufacturers, product, material and application, and manufacturers. The study provides key statistics on the market status, size, share, growth factors of the global Direct-to-Consumer Genetic Testing (DTC-GT) market. The report is formulated with respect to the regional landscape of the market incorporating extensive details about the types and application spectrums of this business space. The document covers the emerging players data, including competitive situation, sales, revenue, and global market share.

Market Outline:

The report analyzes the global Direct-to-Consumer Genetic Testing (DTC-GT) market size and share of each separate segment in the market. Substantial information about the company revenue, production, price, as well as gross margins has been provided. In addition, it delivers details regarding the basic information of every prominent rival in the business, manufacturing base, and the business overview, as well as SWOT examination, sales, value, capacity, regional market examination, and market forecast for 2020 to 2026 time-period. The key geographical regions are analyzed in terms of the parameters such as production, market share in terms of the manufacturers as well as with regards to application and type. A detailed analysis of the market drivers and the emerging regional markets has also been segmented separately in the report.

DOWNLOAD FREE SAMPLE REPORT: https://www.marketsandresearch.biz/sample-request/54613

Based on the product types, market types split into: Over-the-Counter (OTC) Channel, Online Channel

By application, the market is split into: Ancestry-based Genetic Tests, Health and Wellness-based Genetic Tests, Entertainment-based Genetic Tests,

Our best analysts have surveyed the market report with the reference of inventories and data given by the key players: Family Tree DNA, MyHeritage, EasyDNA, Ancestry.com LLC, 24Genetics, Dante Labs, Atlas Biomed, Genebase, Mapmygenome,

Market size segmentation by region & countries: North America (United States, Canada and Mexico), Europe (Germany, France, UK, Russia and Italy), Asia-Pacific (China, Japan, Korea, India and Southeast Asia), South America (Brazil, Argentina, Colombia etc.), Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)

Market Executive Outline: This section comprises the key investigations, market development rate, serious scene, market drivers, patterns, and issues notwithstanding the naturally visible pointers. It discusses gross margin, sales, revenue, production, market share, CAGR, and market size by region. The report offers a complete forecast of the global Direct-to-Consumer Genetic Testing (DTC-GT) Market by product, application, and region.

ACCESS FULL REPORT: https://www.marketsandresearch.biz/report/54613/global-direct-to-consumer-genetic-testing-dtc-gt-market-2020-by-company-regions-type-and-application-forecast-to-2026

What Benefits Does This Report Provide?

Customization of the Report:

This report can be customized to meet the clients requirements. Please connect with our sales team ([emailprotected]), who will ensure that you get a report that suits your needs. You can also get in touch with our executives on +1-201-465-4211 to share your research requirements.

About Us

Marketsandresearch.biz is a leading global Market Research agency providing expert research solutions, trusted by the best. We understand the importance of knowing what global consumers watch and buy, further using the same to document our distinguished research reports. Marketsandresearch.biz has worldwide presence to facilitate real market intelligence using latest methodology, best-in-class research techniques and cost-effective measures for worlds leading research professionals and agencies. We study consumers in more than 100 countries to give you the most complete view of trends and habits worldwide. Marketsandresearch.biz is a leading provider of Full-Service Research, Global Project Management, Market Research Operations and Online Panel Services.

Contact UsMark StoneHead of Business DevelopmentPhone: +1-201-465-4211Email: [emailprotected]Web: http://www.marketsandresearch.biz

Read this article:
Global Direct-to-Consumer Genetic Testing (DTC-GT) Market 2020 by Company, Regions, Type and Application, Forecast to 2026 - Cole of Duty

Dr Luyun Jiang, Technology Analyst at IDTechEx, recently published this article following the release of the new IDTechEx report, "COVID-19 Diagnostics".

Viruses were once known as "contagious living fluids", strange infectious substances capable of slipping through the finest of filters unnoticed. SARS-CoV-2, the coronavirus responsible for the COVID-19 pandemic is indeed slipping through every layer of society, leaving behind severe public health and economic crises. Unlike in the influenza pandemic in 1918, today we are better equipped to identify the elusive bug, with the toolbox of molecular diagnostics and lateral flow assays.

Since the full genome sequencing of the SARS-CoV-2, many national laboratories have identified, in record time, regions of the genome amenable for genetic testing. The golden standard adopted by national laboratories around the world following the WHO protocol to detect the virus in individuals, is based on detecting genetic material specific to SARS-CoV-2 viruses in a person's nasopharyngeal secretions. The main tool for such genetic tests is the Reverse Transcription Polymerase Chain Reaction (RT-PCR). Primer strands that hybridise specifically to the SARS-CoV-2 genome, together with fluorescent probes, help amplify and detect the viral load present in a patient. RT-PCR, normally performed in a real-time quantitative qRT-PCR machine for live fluorescent read-out, constitutes the core element of the testing effort being deployed at the moment across the globe. Clinical laboratories with the necessary equipment and technical know-how to perform RT-PCR are leading this diagnosis effort.

However, not all countries are prepared, neither logistically or with enough equipment and capacity to perform mass testing. An important bottleneck is the short supply of certain ancillary reagents needed to prepare samples for RT-PCR test. RNA extraction kits, for example, are needed for extracting the viral RNA from the sample. The shortage of such supplies, the long processing time and the need to become self-sufficient, has led to many laboratories to try to circumvent some steps in the protocol and to come up with new approaches to reach the testing targets that have been set by policymakers and healthcare officials.

The need for universal and massive testing across the population has led to a race for technology innovations for COVID-19 diagnostics. The newly launched IDTechEx report, "COVID-19 Diagnostics", surveys the technology landscape, with an in-depth analysis of the technology innovations that are enabling a quick access to COVID-19 diagnosis in response to the global pandemic.

Point-of-care molecular diagnostics (POC MDx) are portable devices that perform molecular diagnosis away from central labs. Microfluidics is the key technology behind POC MDx, which controls the motion of small amounts of fluids in microchannels. Microfludic cartridges enable the miniaturisation of devices and introduces automation in the sample handling and detection processes. Some POC MDx devices use isothermal amplification of nucleic acid as an alternative to PCR devices. Isothermal amplifaction bypasses the need of thermal cycling and reduces the detection time from around 2 hours to just 5 min (Abbott ID Now system). Various isothermal amplifaction methods have been adopted for COVID-19 diagnostics. Complex design and unspecific amplification hinder the widespread use of this method. "COVID-19 Diagnostics" provides a deep insight and comparison into the technologies, innovations and current progress on POC MDx and isothermal amplification.

Apart from the time consuming thermal cycling, real-time fluorescent detection is another limitation for low-cost and portable diagnosis tools. Lateral flow assays (both fluorescent or colorimetric), electrochemical detection and microbead-based arrays are integrated with thermal cyclers (PCR reaction) to detect the amplified genetic products. These hybrid systems enable faster, cheaper and palm-size devices for COVID-19 detection at the expense of sensitivity and specificity. More recently, CRISPR-Cas (gene-editing tool based on specific gene recognition) and DNA sequencing techniques show the potential for highly sensitive and selective hybrid systems, as highlighted in "COVID-19 Diagnostics".

Resonating with the message of the WHO director general: "test, test and test", these innovations offer the tools to stop the current outbreak, as well as to prevent future outbreaks, by effective diagnostics and surveillance testing.

For more information, please visit http://www.IDTechEx.com/COVID or contact us at research@IDTechEx.com.

Follow this link:
Fighting the COVID-19 fire with molecular diagnostics innovations - Cambridge Network

New York, April 30, 2020 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Global Hematologic Malignancies Testing Market: Focus on Product, Disease, Technology, End User, Region/Country Data and Competitive Landscape Analysis and Forecast, 2019-2025" - https://www.reportlinker.com/p05829157/?utm_source=GNW What are the underlying structures resulting in the emerging trends within the global hematologic malignancies testing market? How is each segment expected to grow in the global hematologic malignancies testing market during the forecast period and what is the estimated revenue to be generated by each of the segments by the end of 2025? What are the key developmental strategies which are implemented by the major players in order to sustain in the competitive market? What are the key regulatory implications in developed and developing regions for hematologic malignancies testing? Who are the leading players with significant offerings to the global hematologic malignancies testing market? What is the current market dominance for each of these leading players? What would be the compound growth rate witnessed by the leading players in the market during the forecast period 2019-2025? What are the key applications in global hematologic malignancies testing market? What are the major segments of these applications? Which are the dominant disease areas of the global hematologic malignancies testing market? Which is the fastest growing disease area in the global hematologic malignancies testing market? Who are the key manufacturers and service providers in the global hematologic malignancies testing market, and what are their contributions? What is the growth potential of each major hematologic malignancies testing solution provider? What is the scope of the global hematologic malignancies testing market in North America, Europe, Asia-Pacific, Latin America, and Middle East and Africa?

Global Hematologic Malignancies Testing Market Forecast, 2019-2025

The hematologic malignancies testing industry analysis projects the market to grow at a significant CAGR of 15.24% during the forecast period, 2019-2025. The hematologic malignancies testing market generated $1,754.8 million revenue in 2018, in terms of value.

The hematologic malignancies testing market growth has been primarily attributed to the major drivers in this market such as rising incidence of hematologic malignancies, increasing adoption of inorganic growth strategies in the market, favorable reimbursement scenario in the global hematologic malignancies testing market, and increasing funding in hematologic malignancies testing market.However, there are significant challenges which are restraining the market growth.

These challenges include high pricing pressure, lack of trained professionals, and issues pertaining to the analytical validity of genetic testing for cancers.

Expert QuoteThe development of specialized kits has achieved huge success over the past year with NGS and FISH based kits now available across major regions proving the potential to screen malignancies at an early stage.

Scope of the Market Intelligence on Hematologic Malignancies Testing MarketThe hematologic malignancies testing market report provides a holistic view of the market in terms of various factors influencing it, including product optimization, and technological advancements.

The scope of this report is centered upon conducting a detailed study of the products and manufacturers allied with the market. In addition, the study also includes exhaustive information on the unmet needs, perception on the new products, competitive landscape, market share of leading manufacturers, growth potential of each underlying sub-segment, and company, as well as other vital information with respect to global hematologic malignancies testing market.

Market SegmentationThe hematologic malignancies testing market segmentation (on the basis of product) is further segmented into kits and services.

The hematologic malignancies testing market segmentation (on the basis of disease) is segmented into leukemia, lymphoma, multiple myeloma, myeloproliferative neoplasms, and myelodysplastic syndromes.

The hematologic malignancies testing market segmentation (on the basis of technology) is segmented into next-generation sequencing (NGS), polymerase chain reaction (PCR), fluorescence in situ hybridization (FISH), immunohistochemistry (IHC).

The hematologic malignancies testing market segmentation (on the basis of end user) is segmented into specialty clinics and hospitals, diagnostic laboratories, reference laboratories, and research institutions.

Key Companies in the Hematologic Malignancies Testing MarketThe key manufacturers who have been contributing significantly to the Hematologic malignancies testing market include Abbott Laboratories, Adaptive Biotechnologies, ArcherDX, Inc., ARUP Laboratories, ASURAGEN, INC., Bio-Rad Laboratories, Inc., Cancer Genetics Inc., Sysmex Corporation, F. Hoffmann-La Roche AG, Illumina, Inc, Invivoscribe, Inc., Invitae Corporation, ICON plc, NeoGenomics Laboratories, Inc., and QIAGEN N.V., among others.

Countries Covered North America U.S. Canada Europe Germany U.K. France Italy Spain Rest-of-Europe Asia-Pacific China Japan India Australia Singapore Rest-of-APAC Rest-of-the-World Latin America Middle East and AfricaRead the full report: https://www.reportlinker.com/p05829157/?utm_source=GNW

About ReportlinkerReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.

__________________________

Read more here:
The hematologic malignancies testing industry analysis by BIS Research projects the market to grow at a significant CAGR of 15.24% during the forecast...

An urgent warning has been issued to people living in a western Sydney local government area after health authorities identified a strain of COVID-19 responsible for more than a dozen deaths.

People in the Penrith LGA have been asked to come forward for testing after the strain was identified to have been associated with known COVID-19 clusters.

The strain of the virus is the same one thats been identified at the Newmarch House in Caddens, where 59 people have tested positive for COVID-19 and 13 people have died.

Were uring people in the Penrith local government area to be a focus for increased testing, NSW Chief Medical Officer Dr Kerry Chant said on Friday.

In the video below: NSW Premier confirms nine new coronavirus cases

We are aware that our genetic testing of the virus has indicated there has been a virus strain of COIVD-19 circulating in that broader community and we have seen it enter, for instance, the Newmarch house, but also its been associated with other clusters in that area.

So anyone in the Penrith LGA, I particularly urge you, if youve got respiratory symptoms, come forth and get tested.

Premier Gladys Berejiklian said she wants at least 8,000 people to come forward for testing every day across the state and she doesnt want to see a dip on the weekend.

Our goal is to have as many people tested every day of the week as possible and we want to get close to that 8000 number and even exceed it, she told reporters on Friday.

So please come forward even if you have the mildest symptoms.

More on 7NEWS.com.au

You dont need to wait until Monday. You could be unintentionally passing on the disease without knowing you have it.

Nine new cases of coronavirus were announced on Friday, bringing the states total number of cases to 3,025.

Of the new cases, three are from a known cluster or source, one was acquired overseas and another one remains under investigation.

View post:
Coronavirus in NSW: Penrith residents urged to get tested as COVID-19 strain behind deadly outbreak spreads - 7NEWS.com.au

The global Direct-to-Consumer (DTC) Genetic Testing Market is expected to surge at a steady CAGR in the coming years.The publication offers an insightful take on the historical data of the market and the milestones it has achieved. The report also includes an assessment of current market trends and dynamics, which helps in mapping the trajectory of the global Direct-to-Consumer (DTC) Genetic Testing market. Analysts have used Porters five forces analysis and SWOT analysis to explain the various elements of the market in absolute detail. Furthermore, it also studies the socio-economic factors, political changes, and environmental norms that are likely to affect the global Direct-to-Consumer (DTC) Genetic Testing market.

A recent market study published by Report Hive Research discusses the current and future prospects of the Direct-to-Consumer (DTC) Genetic Testing market. Further, the report includes an in-depth COVID-19 pandemic analysis and various factors that are likely to control the growth trajectory of the Direct-to-Consumer (DTC) Genetic Testing market in the upcoming years. In addition, a qualitative and quantitative assessment of the various market segments is enclosed in the report and accurately represented in the form of tables, graphs, and figures. In addition, the information has analysed with the help of primary as well as secondary research methodologies to offer a holistic view of the target market. Likewise, the Direct-to-Consumer (DTC) Genetic Testing Market report offers an in-house analysis of global economic conditions and related economic factors and indicators to evaluate their impact on the Direct-to-Consumer (DTC) Genetic Testing Market historically.

The Direct-to-Consumer (DTC) Genetic Testing market study published in the report is in a chapter-wise format to ease of the readability and complexity of the data covered. Each chapter is further categorized into its respective segments containing well-structured data. The competitive scenario displayed includes major market player details such as, company profile, end-user demand, import/export volume, sales data, etc. The report also covers the business strategies applied by different players, which will be a great addition for smart business decisions.

Request a sample of this report @ https://www.reporthive.com/request_sample/2292341

This study covers following key players:

23andMedeCODEmeDNA DTCGeneByGeneGenecodebook OyGenetrainerMD RevolutionMyriad GeneticsNavigenics

Essential Findings of the Report

The report is a mindful assortment of vital factors that lend versatile cues on market size and growth traits, besides also offering an in-depth section on opportunity mapping as well as barrier analysis, thus encouraging report readers to incur growth in global Direct-to-Consumer (DTC) Genetic Testing Market. This detailed report on Direct-to-Consumer (DTC) Genetic Testing Market largely focuses on prominent facets such as product portfolio, payment channels, service offerings, applications, in addition to technological sophistication. All the notable Direct-to-Consumer (DTC) Genetic Testing Market specific dimensions are studied and analysed at length in the report to arrive at conclusive insights. Apart from highlighting these vital realms, the report also includes critical understanding on notable developments and growth estimation across regions at a global context in this report on Direct-to-Consumer (DTC) Genetic Testing Market.

Besides these aforementioned factors and attributes of the Direct-to-Consumer (DTC) Genetic Testing Market, this report specifically decodes notable findings and concludes on innumerable factors and growth stimulating decisions that make this Direct-to-Consumer (DTC) Genetic Testing Market a highly profitable. A thorough take on essential elements such as drivers, threats, challenges, opportunities are thoroughly assessed and analysed to arrive at logical conclusions. Additionally, a dedicated section on regional overview of the Direct-to-Consumer (DTC) Genetic Testing Market is also included in the report to identify lucrative growth hubs. These leading players are analysed at length, complete with their product portfolio and company profiles to decipher crucial market findings.

Market segment by Type, the product can be split into:

Genome Data Bank Material ModelIndividual Health Planning ModelComprehensive Genome Tests ModelMedical Precision Tests ModelRestricted Trait Tests Model

Market segment by Application, split into:

Doctor OfficeInternetOthers

The report also lists ample correspondence about significant analytical practices and industry specific documentation such as SWOT and PESTEL analysis to guide optimum profits in Direct-to-Consumer (DTC) Genetic Testing Market. In addition to all of these detailed Direct-to-Consumer (DTC) Genetic Testing Market specific developments, the report sheds light on dynamic segmentation based on which Direct-to-Consumer (DTC) Genetic Testing Market has been systematically split into prominent segments encompassing type, application, technology, as well as region specific segmentation of the Direct-to-Consumer (DTC) Genetic Testing Market.

Some Major TOC Points:

1 Report Overview

2 Global Growth Trends

3 Market Share by Key Players

4 Breakdown Data by Type and ApplicationContinued

Why Purchase from Report Hive Research?

For Enquiry before buying [emailprotected] https://www.reporthive.com/request_customization/2292341

Get in Touch with Us :

Report Hive Research

500, North Michigan Avenue,

Suite 6014,

Chicago, IL 60611,

United States

Website: https://www.reporthive.comEmail: [emailprotected]Phone:+1 312-604-7084

Why Go For Report Hive Research?

Report Hive Research delivers strategic market research reports, statistical surveys, industry analysis and forecast data on products and services, markets and companies. Our clientele ranges mix of global business leaders, government organizations, SMEs, individuals and Start-ups, top management consulting firms, universities, etc. Our library of 700,000 + reports targets high growth emerging markets in the USA, Europe Middle East, Africa, Asia Pacific covering industries like IT, Telecom, Semiconductor, Chemical, Healthcare, Pharmaceutical, Energy and Power, Manufacturing, Automotive and Transportation, Food and Beverages, etc. This large collection of insightful reports assists clients to stay ahead of time and competition. We help in business decision-making on aspects such as market entry strategies, market sizing, market share analysis, sales and revenue, technology trends, competitive analysis, product portfolio, and application analysis, etc.

Read more from the original source:
Direct-to-Consumer (DTC) Genetic Testing Market 2020 (Impact of COVID-19): Which product is expected to gain the highest share? - Latest Herald

Global Predictive Genetic Testing market report presents an overview based on the historic data. Report provides market key segmentation such as product type, industry, key regions and key companies. On the basis of historic data, market size has been forecasted in terms of revenue from base year 2019 to 2025. Research report includes in detailed study of growth factors, restrains, opportunities, technological innovations and trends of the global Predictive Genetic Testing market. Report also covers the impact of drivers and restrains region and country wise and the opportunities during the forecast period.

Top Leading Key Players are:Agilent, Technologies, Inc., BGI Genomics, F.Hoffman-La Roche Ltd., Genes In Life., Invitae Corporation, Illumina, Inc., 23andMe, Myriad Genetics, Inc., Pathway Genomics and Thermo Fisher Scientific, Inc.

Get Sample Copy of this Report:https://www.adroitmarketresearch.com/contacts/request-sample/1276

In addition, report on global Predictive Genetic Testing market presents strategic analysis and ideas for new entrants using historic data study. Thus report provides estimation about the market size, revenue, sales analysis and opportunities based on the past data for current and future market status. Report covers analysis of different enterprises as part of global Predictive Genetic Testing market. There are some important tools for any market movement. Also report forecasts the market size of global Predictive Genetic Testing market in Compound Annual Growth Rate in terms of revenue during the forecast period.

The main objective of this research report is to present the comprehensive analysis about the factors which are responsible for the growth of the global Predictive Genetic Testing market. The study report covers all the recent developments and innovations in the market for a Predictive Genetic Testing. The global Predictive Genetic Testing market is likely to provide insights for the major strategies which is also estimated to have an impact on the overall growth of the market. Several strategies such as the PESTEL analysis and SWOT analysis is also being covered for the global market. These strategies have an impact on the overall market.

Browse the complete report @https://www.adroitmarketresearch.com/industry-reports/predictive-genetic-testing-market

The research report on global Predictive Genetic Testing market ensures users to remain competitive in the market. Also report helps to identify the new innovations and developments by existing key players to increase the growth of the global Predictive Genetic Testing market. This market study report covers all the geographical regions where competitive landscape exists by the players such as North America, Europe, Latin America, Asia-Pacific and Middle East Africa. Thus report helps to identify the key growth countries and regions.

In addition, study report covers all the important geographical regions which have good market growth of global Predictive Genetic Testing market. Government organizations and policy makers are taking initiatives to promote the global Predictive Genetic Testing market thus it is boosting the growth of global Predictive Genetic Testing market. Furthermore, report presents the end users on the basis of enterprise size for the global Predictive Genetic Testing market. Report is beneficial for any user of any department as report provides strategic analysis for the expansion of the business cross the globe.

For Any Query on the Predictive Genetic Testing Market:https://www.adroitmarketresearch.com/contacts/enquiry-before-buying/1276

About Us :

Adroit Market Research is an India-based business analytics and consulting company. Our target audience is a wide range of corporations, manufacturing companies, product/technology development institutions and industry associations that require understanding of a markets size, key trends, participants and future outlook of an industry. We intend to become our clients knowledge partner and provide them with valuable market insights to help create opportunities that increase their revenues. We follow a code Explore, Learn and Transform. At our core, we are curious people who love to identify and understand industry patterns, create an insightful study around our findings and churn out money-making roadmaps.

Contact Us :

Ryan JohnsonAccount Manager Global3131 McKinney Ave Ste 600, Dallas,TX 75204, U.S.APhone No.: USA: +1 972-362 -8199 / +91 9665341414

Read the original post:
Predictive Genetic Testing Market 2020 Size By Product Types, End-Users, Regional Outlook, Growth Potential, Price Trends And Forecast To 2025 -...

You know that file you got from Ancestry or 23andMe that contains a digital copy of your entire genetic code? Imagine that you upload it to a site, and five minutes later it spits out a report. Bad news it says your risk from the coronavirus is a glaring red HIGHER, meaning that according to a potpourri of genetic markers, youre more likely to have a severe, potentially deadly case of COVID-19.

Thats the idea behind a free genetic analysis offered by Sequencing.com, a genetic testing company thats offering personalized, DNA-based coronavirus warnings.

A person who looks to be low risk on a non-genetic level or seems like they could be pretty okay if they get COVID-19, we know that their genes are putting them on the path to a more severe disease, Sequencing CEO and clinical geneticist Brandon Colby told Futurism.

One of the major challenges of the coronavirus pandemic has been identifying whos at a greater risk for a disease that remains difficult to treat. At first, the outbreak seemed to be most dangerous for the elderly or people with underlying health conditions. But over time, more reports emerged of younger, healthier people coming down with severe and sometimes fatal cases.

Colbys goal is to personalize coronavirus testing by providing reports catered specifically to a individuals genetic code. With that, the screenings could bring to light warnings signs that might have previously flown under the radar for patients who otherwise seem healthy.

Colby told Futurism that he hopes the reports will convince people with high genetic risk factors to exercise greater caution. And if they do start to feel sick, he says, the report could spur them to seek treatment immediately.

That person may have genes that put them at high risk, and thats really the power of this report, Colby told Futurism. Without this report, that would have been a major question.

While clinical trials about how to best treat COVID-19 are only beginning to emerge, geneticists have already learned much about the structure, genetic code, and biological mechanisms of the virus that causes it, SARS-CoV-2. Colby and his team used that research to develop their predictive reports.

Because SARS-CoV-2 is so genetically similar to SARS-CoV-1, the coronavirus that causes SARS, the Sequencing team also pulled from the far more expansive body of research on that virus as well, since the same genes seem to be linked to a greater risk of infection and more severe symptoms of both diseases.

This research is still preliminary and this analysis is based on preliminary genetic associations, Colby said. If the pandemic was not such a crisis, then this would be something that we would want more research to come out upon. We would probably put this up there in a beta format, and that would be very clear.

But due to the crisis, the urgency, we are utilizing these preliminary studies and making sure that people understand that these are preliminary, he added. Were utilizing what information we currently have available to make it useful at a time when its needed.

Supplementing their research with existing studies on the SARS virus may make for a more robust tool, but genetic experts werent entirely convinced by the idea of an online genetic test for COVID risk.

I think the key here is that there are both genetic and environmental factors that contribute to an individuals personal susceptibility, Boston University geneticist Shoumita Dasgupta, whos unaffiliated with Sequencing, told Futurism. We know this from other pathogens as well. Neither one alone will be enough to be completely protective, but the combination of public health measures and biomedical research on genetic risk factors can together help us navigate our way out of this situation.

Genetics rarely gives you a 100 percent foolproof predictive ability, Dasgupta added.

Certainly, comparative genomics can give insight from how genes work in other systems, but since viruses evolve quickly, its possible that those components may work together slightly differently in the novel coronavirus, Dasgupta added.

Because genes cant possibly tell the whole story, Sequencings report also weighs non-genetic risk factors, like age, smoking habits, and existing medical conditions, which Dasgupta described as a good start. Colby told Futurism that even more environmental factors, like stress, will be included in a major update to the reports expected to go live on Friday.

Colby said that his team will add new findings as they encounter them, making the reports more accurate and robust. Anyone who got a genetic profile from Sequencing might get a notification in the future that their report has changed as new research comes in, especially after that new update.

Even with the knowledge that these reports are based on preliminary findings and could change just as the pandemic continues to change and surprise us, Colby hopes that the personalized reports and warnings will inspire people to better protect themselves.

If you dont know that youre at very high risk, you think, Hey Im 30 years old, I dont have any health problems, I dont smoke, Im gonna go shopping today. Im gonna go outside and potentially expose myself, that decision may be altered once you go and see these reports, Colby said.

Read the original post:
Free DNA Test Claims to Warn Whether COVID Is Likely to Kill You - Futurism

April 29, 2020 |April featured exciting new, products, and partnerships from around the bio-IT community from innovating companies, organizations, and universities, including Discngine and Insilico Medicine, as well as recent attempts to combat COVID-19.

The bio-IT community has been working around the clock to address the COVID-19 pandemic. Companies and universities such as MIT, CSIRO, and Oak Ridge National Laboratoryhave concentrated their efforts to develop a COVID-19 Research Database, specialized proteins to combat immune overreaction to the virus, promising animal models, and much more. Roundup

Digital Scienceannounced a partnership with Zhipu.AI to conduct data challenges and collaborate in building a COVID-19 information portal. This strategic collaboration will see the two companies work together on a broad range of projects over the next several years. Some of the existing opportunities planned for the collaboration include joint hosting of a new set of data challenges centered around scholarly communications problems such as name disambiguation; and bringing together advanced analysis tools from both companies to create deeper insights for the sector. Collaboration will be a central theme of the new relationship and will see Digital Science's Overleafmade more seamlessly available to more Chinese users, enabling them to create, edit and publish their research all from one browser using the real-time collaborative LaTeXeditor. Press release

OptraHEALTHannounced that Advagenixhas implemented GeneFAXto assist their patients with accurate information about genetic health. GeneFAX, a flagship product of OptraHEALTH, is an AI-powered HIPAA compliant, knowledge platform for genetic health with BOT interfaces. By employing this AI-enabled technology BOT, AdvaGenix will collect information about their patients family history of cancer as well as understanding reproductive health issues. Patients will then get automatically directed to the right tests to AdvaGenix through GeneFAX. There has been a heavy focus on enabling direct-to-consumer genetic testing over the last few years, but we cannot forget that most of this testing is still being ordered in a clinic. We want to make sure that physicians, genetic labs and patients are at the center of everything we develop, saidDr. Gauri Naik, Co-Founder & Chief Executive Officer, OptraHEALTH, in a press release. GeneFAX will assistAdvaGenixto better engage with their patients for Hereditary Cancer & Reproductive Genetic Health diagnostic testing andpromote their testing panels in appropriate healthcare settings. Press release

Insilico Medicineannounced it has entered into a research collaboration with Boehringer Ingelheimto utilize Insilico's generative machine learning technology and proprietary Pandomics Discovery Platformwith the aim of identifying potential therapeutic targets implicated in a variety of diseases. "Insilico Medicine is very impressed with the Research Beyond Borders group at Boehringer Ingelheim capabilities in the search of potential drug targets. In this collaboration, Insilico will provide additional AI capabilities to discover novel targets for a variety of diseases to benefit the patients worldwide. We are very happy to partner with such an advanced group," saidAlex Zhavoronkov, PhD, founder, and CEO of Insilico Medicine, in a press release. "We believe that Insilico's exclusive Pandomics platform will provide huge boost to our ability to explore and identify drug targets. We look forward to using AI to significantly improve the drug discovery process and contribute to human health," Dr.Weiyi Zhang, Head of External Innovation Hub, Boehringer Ingelheim GreaterChina, said in an official statement. Press release

Lifebit Biotechannounced a major new release of Lifebit CloudOS, the end-to-end cloud operating system that accelerates genomics research and delivers enriched insights in personalized medicine. Building upon its federated technology, Lifebit CloudOS 2.0 integrates the Biobank Data Browser, allowing users to store and query massive sets of genomic, phenotypic, multi-omic, medical record and other structured data generated by biobanks, such as UK Biobank. Facilitating data exploration, analysis, and discovery, Lifebit CloudOS 2.0 empowers R&D teams to leap forward research and cures. The Biobank Data Browser enables researchers to effortlessly explore and analyze the full complement of genomics and phenotypic data available in biobanks. In addition, the powerful JupyterLabintegration eases barriers to complex data analyses for researchers of all levels. Since it is built to scale to 10+ million individuals and 3+ billion variants, Lifebit CloudOS 2.0 seamlessly handles increasing biobank data collections and data points.More info

Biofourmisannounced it has finalized an agreement to acquire Gaido Healthfrom Takeda Pharmaceuticals, a strategic deal that expands Biofourmis' portfolio in the oncology space. Gaido HealthaLos Angeles-area based digital therapeutics company focused on the oncology marketwas part of Takeda Digital Ventures, Takeda's corporate technology investment and incubation arm. The acquisition seeks to address a disconnected oncology care pathway that has led to more than 30% of patients on chemotherapy being readmitted to the hospital or requiring a visit to the emergency department. Inthe United Statesalone, 1.6 million patients are diagnosed with cancer each year, and the total cost of care is expected to rise to$170 billionin 2020. "Biofourmis' digital therapeutics solution for oncologynow bolstered with this acquisition of Gaido Healthis based on an innovative approach that continuously monitors patients' physiology biomarkers and symptoms, detects early signs of complications, and arms care teams with tools to intervene early to prevent medical crises, improve outcomes and lower costs," said Kuldeep Singh Rajput, CEO of Biofourmis, in a press release. "The platform also empowers patients with cancer to self-manage symptoms using Biofourmis' artificial intelligence [AI]-based Biovitalstreatment algorithms, which improves engagement and quality of life." Gaido Health's solution, which will be supported by Biofourmis' existing Biovitals platform, combines information on vital signs collected via remote monitoring in the home, patient surveys and analytics to detect early signs of complications in patients with cancer who have been recently discharged from the hospital. Gaido Health's AI-based algorithms detect signs of complications to inform the clinician, enabling earlier interventions. Press release

VeracyteandYale Universityannounced an exclusive licensing agreement to advance the first genomic test for predicting disease progression in patients with idiopathic pulmonary fibrosis (IPF). The agreement gives Veracyte rights to a 52-gene signature developed by Yale researchers, for use on the nCounter FLEX Analysis System Veracytes exclusively licensed diagnostics platform. Veracyte plans to make the non-invasive, blood-based test available as a complement to its Envisia Genomic Classifier, as part of a comprehensive offering to aid in the diagnosis and treatment of patients with IPF. The 52-gene signature in peripheral blood, developed by Dr. Naftali Kaminski, chief of the Section of Pulmonary, Critical Care and Sleep Medicine in the Department of Medicine at Yale Universitys School of Medicine, and collaborators, is shown to predict rapid disease progression among patients with IPF. We are excited to advance groundbreaking research from Dr. Kaminski and his team into a commercially available, first-of-its-kind genomic test that may further help guide care for patients with IPF, said Bonnie Anderson, Veracytes chairman and chief executive officer, in a press release. The addition of prognostic information to our Envisia classifier, which is already available as a genomic tool to help improve IPF diagnosis, enhances the value of this test for physicians and patients as we prepare it for global market expansion on the nCounter platform in 2021. This agreement was enabled by Veracytes December 2019 acquisition of the exclusive global diagnostics rights to the nCounter platform, and further underscores the strategic value of that transaction to our company. Press release

Scopio Labsannounced it has received CE mark certification for its X100 Full Field Peripheral Blood Smear (Full Field PBS)all-digital morphology analysis platform. As the first digital microscope to scan and analyze entire regions of interest from a slide in high resolution, Full Field PBS enables remote consultation and includes a computer-vision based decision support system, advancing manual microscopy into the digital age. Accelerating the diagnostic process by scanning and digitizing large areas of the slide in high resolution, Scopio Labs helps facilitate efficient review of digital slides and uses its built-in AI tools to compile a detailed report that can also be remotely shared with experts. The Full Field PBS offers an end-to-end decision-support tool for clinicians. Its digitized scans are reconstructed with cutting-edge computational photography tools at 100X equivalent magnification and at oil-immersion resolution levels. Built-in machine learning tools then pre-classify cells within the slide and create a data summary of the results. The image data, as well as the data summary, can be reviewed by experts in multiple locations in the lab that generated the samples, and in other labs within the organization's network. Scopio Labs platforms are scalable, suit a variety of both large and small labs, easily integrate with standard processes and are market-ready. Press release

Discngineannounced that Sosei Heptareshas selected its 3decisionsoftware to be part of a structural GPCR chemogenomics platform. Sosei Heptares will use 3decision to unify the public Protein Data Bank (PDB)structures with internal unpublished GPCR structures used for structure-based drug discovery, thus allowing Sosei Heptares to combine the wealth of its unique structural information, sequence information and knowledge of chemical ligand space in GPCRs. 3decision will enable Sosei Heptares scientists to derive unprecedented structural GPCR insights more efficiently from the structural data at hand. This knowledge will directly benefit the internal structure-based drug design (SBDD) projects and help to further reinforce Sosei Heptares strong expertise in GPCR structural cheminformatics. In addition, 3decision will make it easier for Sosei Heptares to combine the unique structural information with GPCR modelling, cheminformatics capabilities, mutagenesis data and the information provided by their StaR (Stabilized Receptor) technology. For example, 3decision will allow Sosei Heptares to easily visualize and analyze mutagenesis data in 3D, via a web-accessible front-end. Press release

Genomenonannounced that the latest release of theMastermind Genomic Search Engineincludes the ability to search by therapy. Mastermind users can now query the comprehensive database of genomic evidence for over 180,000 drugs, therapies, and other interventions. This new offering furthers Genomenons ability to catalogue a complete dataset of all Genomic Associations supported by medical evidence. These associations help clinical labs more accurately and rapidly diagnose patients, and pharmaceutical companies make ground-breaking discoveries in the effective treatment of cancer and other genetic diseases. Mastermind was launched in 2017 with the ability to uncover associations between diseases, genes, and variants, and has since addedACMG/AMP classification,phenotypes, and now therapies. Each new component of association data increases the power of Mastermind to allow users to find genetic evidence, test or generate hypotheses, and draw clinical conclusions with confidence. Searching by therapy provides significant value for oncologists making decisions on third-line therapies, where approved drugs or clinical trials are no longer effective for a cancer patient. Finding a comprehensive list of all therapies in the medical research tied to a cancer patients genetic make-up is invaluable for treating these late-stage cancer patients. The new search capability is also highly useful for clinicians making diagnostic and treatment decisions for patients with rare diseases. There are currently less than 800 FDA approved therapies for over 7,000 rare diseases, leaving many patients without an approved treatment option. In these cases, clinicians are required to scour the medical literature to find therapies associated with the patients genetic profile; a time-consuming and often fruitless task. Press release

See the rest here:
COVID-19, Insilico Medicine, Discngine, And More: News From April 2020 - Bio-IT World

Idaho Department of Fish and Game recently confirmed that tracks near Grangeville came from a grizzly bear, a species not common in that part of the state, according to an agency news release.

The tracks were spotted April 18 about seven miles south of Grangeville in the Fish Creek Meadows area, officials said. A hair sample was collected near the tracks and sent to a lab for genetic testing, but results won't be available for several months.

"We don't know if it's going to stay," said Jon Rachael, state wildlife manager for Fish and Game, in a phone interview. "We don't know if it's still there now." According to Fish and Game, it's not the first instance of a bear in the region. A hair sample was collected near White Bird Creek, southwest of Grangeville, in spring of 2019. DNA testing of the sample showed that animal was a young male grizzly that had been radio-collared as a yearling near Idaho's border with Canada in 2017. The bear's collar had fallen off in 2018, so no tracking data was available last year.

"If confirmed as the same bear, this bear is now 4 years old, and it has traveled several hundred miles through Idaho and Montana without any known conflict with people," Fish and Game said in the news release.

Experts say grizzly bears, considered an endangered species in the Lower 48 of the United States, have been expanding their territory in Idaho, Wyoming and Montana for the last decade. Last summer, a male grizzly wearing a tracking collar headed south into the Selway-Bitterroot Wilderness Area, where grizzlies hadn't been seen in nearly a century.

"We don't have a lot of indication of grizzly bears in that area," Rachael said.

Last fall, a hunter captured images on a game camera of what he believes is a grizzly bear in the Newsome Creek area west of Elk City. That's only about 21 miles from Fish Creek Meadows, where Fish and Game found grizzly tracks last weekend. Fish and Game took DNA samples from bear scat in the area, but the results came back positive for a black bear. Rachael said it's possible the animal in the photo was a grizzly and the scat tested belonged to a different animal. He said it's also possible the bear in the photo is the same one that left tracks near Grangeville.

U.S. Fish and Wildlife Service maps from 2018 show grizzly bears are known to be in eastern Idaho near the border of Wyoming, where they sometimes roam from Yellowstone National Park. The bears are also known to be in far North Idaho near the Canadian border.

Visit The Idaho Statesman (Boise, Idaho) at http://www.idahostatesman.com

More here:
Are Grizzly Tracks Near Grangeville From Same Bear Seen Nearby Last Year? - bigcountrynewsconnection.com

DENVER, April 29, 2020 /PRNewswire/ --CCRM Fertility, a global pioneer in fertility science, research and advancement, today announced each of its 11 locations across the U.S. will resume all fertility treatments in accordance with new guidance set forth by American Society for Reproductive Medicine (ASRM) on April 24. Effective immediately, all CCRM Fertility locations are open and seeing both new and existing patients for all treatments, including egg retrievals, embryo transfers, and intrauterine inseminations (IUI), regardless of where they began their fertility journey prior to the global pandemic-related lockdown.

"At CCRM Fertility, we are dedicated to giving families the very best chance to have a baby, but the previous recommendations outlined by ASRM as a result of the novel coronavirus unfortunately paused treatment plans for many patients,"comments CCRM Fertility Founder and Medical Director William Schoolcraft, M.D."We know that the delays caused by COVID-19 have been heartbreaking for our patients, and this new guidance allows us to resume treatment for all patientsso they may continue their journeys toward parenthood as quickly and as safely as possible."

CCRM Fertility is committed to not only helping individuals and couplesbuildtheir families, but also protecting the health and wellbeing of its patientsand staff.In order to continue to provide industry-leading care and outcomes while limiting social exposure and virus transmission, CCRM Fertility has implemented the following measures:

All CCRM Fertility physicians and medical directors will continue monitoring the evolving situation and will stay in close communication with patients. For CCRM Fertility's most up-to-date policies and guidelines on COVID-19, visit ccrmivf.com/covid19/.

To schedule an appointment, call (877) 201-6931 or visit http://www.ccrmivf.com.

About CCRM Fertility

Founded by Dr. William Schoolcraft in 1987, CCRM Fertility is the nation's leader in fertility care and research. CCRM Fertility specializes in the most advanced fertility treatments, with deep expertise in in vitro fertilization (IVF), fertility assessment, fertility preservation, genetic testing, third party reproduction and egg donation. Unlike many other fertility clinics that outsource their specialists and testing needs, CCRM Fertility leverages its own data, as well as a dedicated team of in-house reproductive endocrinologists, embryologists and geneticists in order to deliver industry-leading outcomes. CCRM Fertility operates 11 fertility centers (including 26 offices) throughout North America, serving prospective parents in major metropolitan areas, including Atlanta, Boston, Dallas, Denver, Houston, New York, Northern Virginia, Minneapolis, Orange County, San Francisco Bay Area and Toronto. For more information, visit http://www.ccrmivf.com, become a fan on Facebook, or follow us onInstagram and Twitter.

More here:
CCRM Fertility Resumes All Forms of Treatment for New and Existing Patients - The Grand Junction Daily Sentinel

LITTLE ROCK, Ark. As Governor Asa Hutchinson prepares to announce decisions for when businesses forced to close by the COVID-19 outbreak could possibly restart, there's uncertainty among business leaders.

A trio of Little Rock company owners touched on that uncertainty while being honored by the local Rotary Club for the way they adapted to the outbreak.

"It's been chaos," said Steve Harrison, head of Natural State Labs, which went from genetic testing to drive-up virus testing in a matter of days. "I think is the best way to describe it."

Harrison joined Phil Brandon of Rock Town Distillery, Patrick Schueck of Lexicon Constructors and Fabricators, and Larry Whitman, an engineering professor at UA-Little Rock.

RELATED: Gov. Hutchinson announces plans to reopen state parks, marinas in May

"That's the $64,000 question," said Brandon, who joined many other brewers and distilleries in switching to making hand sanitizer to avoid going from booze to bear market overnight.

"The hand sanitizer we make is primarily alcohol, and we make alcohol everyday. I think the demand is going to be there for quite a while and we'll keep making it as long as there's a market for it."

Dean Whitman and Schueck talked about collaborating to ramp up production of face shield components to meet the demand for personal protective equipment.

RELATED: Little Rock Goodwill housing giant disinfecting units to help recycle PPE

They along with Harrison managed to stay open, though under the "targeted approach" used by the governor, didn't face pressure to shut down. They all spoke of how quickly events unfolded and how quickly they had to respond.

"It's been kind of the wild wild west in terms of where this is going to go," said Harrison, who is now hustling to provide required 48-hour virus testing for the many people green-lighted to get delayed elective surgery.

While those patients rush in, not everyone is in a hurry.

"Some would like to see the restaurants and barber shops in their community opened yesterday. Some would like to see it delayed," the governor said of responses he's heard from mayors ahead of his decision days.

A similar split exists in the business community.

"I think it's pretty evenly divided across the board," said Jay Chesshir, the president of the Little Rock Regional Chamber of Commerce and moderator of the Rotary Club panel. "The want-to and the intent and the desire is there. They just want to do so in a safe manor."

Link:
Arkansas businesses uncertain ahead of governor's announcements to reopen state - THV11.com KTHV

Psomagen, a US company dedicated to genome sequencing technology and DNA testing, said on April 29 it looks to raise at least 57.5 billion won ($47.2 million) in an initial public offering on the Korean bourse.

Under the plan to be listed on Kosdaq, Psomagen seeks to issue 4.2 million new common shares, amounting to a 25 percent stake, and offer them to investors in an IPO set to take place in May. Shinhan Investment is an underwriter of the IPO deal.

The IPO proceeds will be used to boost its entry into a personal genomics business targeting the US market, repay its debt for an acquisition deal and ramp up its logistics infrastructure for its end-to-end genome sequencing solutions.

Psomagen CEO Ryan Kim speaks at a briefing held in Seoul on April 29. (Psomagen)

Psomagens foray into personal genomics business is crucial, as the practice of a precision medicine is increasingly tailored to an individual, Psomagen CEO Ryan Kim told reporters on April 29 in a briefing in Seoul.

(Psomagen) is turning into a health care solution provider powered by big data, based on our genome sequencing capability, he said.

We are witnessing a paradigm shift in US health care system. As the genome sequencing technology gets more sophisticated, its price has been on the decline, so individual health care services are increasingly tailored to analysis and interpretation of the genome of an individual.

Based in Rockville, Maryland, Psomagen has moved to produce genetic testing kits using saliva samples and sell them directly to consumers. It also tapped into microbiome genetic testing solutions using consumers stool samples.

This is a leap forward from its decadeslong effort to focus on research into genome sequencing using technologies such as sanger sequencing and next-generation sequencing.

Having both the College of American Pathologists accreditation and Clinical Laboratory Improvement Amendments certification, the company was the only for-profit entity to join former US President Barack Obamas Trans-Omics for Precision Medicine initiative, according to Psomagen. Kim said the research division is expected to generate a steady return of profits.

The efforts will also be buttressed by its latest acquisition of San Francisco-based biotech company uBiome in 2019, which allowed Psomagen to possess its 246 patent rights and some 300,000 data subjects.

In 2019, Psomagen logged a $4.17 million operating loss and 19.79 million net loss, according to its prospectus. The net loss rose over eightfold largely due to the cost of the uBiome acquisition deal.

Psomagen is expected to become the first company based out of Korea to go public by undergoing an abridged screening procedure by the Korea Exchange. The procedure, special listing on promising business model, allows a companys listing eligibility to be evaluated by the potential of scalability instead of profitability.

Psomagen is a spinoff from Seoul-based genomics service provider Macrogen. If the new shares are issued, Macrogen and its affiliated shareholders will hold a combined 68.7 percent stake. It is part of the 71.53 percent of shares that will be placed under a lockup period for one to three years.

By Son Ji-hyoung (consnow@heraldcorp.com)

Follow this link:
US-based Psomagen eyes at least W57.5b IPO in Korea - The Investor

In this report, the global Predictive Genetic Testing market is valued at USD XX million in 2019 and is projected to reach USD XX million by the end of 2025, growing at a CAGR of XX% during the period 2019 to 2025.

Persistence Market Research recently published a market study that sheds light on the growth prospects of the global Predictive Genetic Testing market during the forecast period (20XX-20XX). In addition, the report also includes a detailed analysis of the impact of the novel COVID-19 pandemic on the future prospects of the Predictive Genetic Testing market. The report provides a thorough evaluation of the latest trends, market drivers, opportunities, and challenges within the global Predictive Genetic Testing market to assist our clients arrive at beneficial business decisions.

The Predictive Genetic Testing market report firstly introduced the basics: definitions, classifications, applications and market overview; product specifications; manufacturing processes; cost structures, raw materials and so on. Then it analyzed the worlds main region market conditions, including the product price, profit, capacity, production, supply, demand and market growth rate and forecast etc. In the end, the Predictive Genetic Testing market report introduced new project SWOT analysis, investment feasibility analysis, and investment return analysis.

Request Sample Report @ https://www.persistencemarketresearch.co/samples/31204

Resourceful insights enclosed in the report:

The major players profiled in this Predictive Genetic Testing market report include:

key players in the predictive genetic testing market. The significant competitive strength of the existing players in the evolving landscape of the global predictive genetic testing market is anticipated to offer new prospect in widening the application of the predictive genetic testing, substantially driving predictive genetic testing market growth. The key manufacturers of the predictive genetic testing are greatly concentrated on the technical edification of the end users to improve consumer outcomes. Furthermore, the adoptions of advanced predictive genetic testing services is expected to create lucrative growth opportunities for the service and third-party market competitors. Growing inclination toward trend in predict is prevention is estimated to offer growth opportunity for Predictive genetic testing market. Selection of treatment regimen with Predictive genetic testing is projected to aid capturing higher share in Predictive genetic testing market.

Geographically, global Predictive genetic testing market is segmented into seven key regions viz. North America, Latin America, Europe, South Asia, East Asia Oceania and Middle East & Africa. North America is prominent region in Predictive genetic testing Market. Advancement in genetic care facilities, higher adoption to lifestyle changes, increase awareness about genetic disease, increase in preventative care and favorable government policies have improved the regulatory scenario for predictive genetic testing devices in north America. Additionally in Asia pacific region considerably higher market growth rate is expected due to constantly rising population and higher incidence of genetic abnormality. Relatively affecting the Predictive genetic testing market.

Some of the major key players competing in the global Predictive genetic testing Market are Myriad Genetics, Inc., Abbott Laboratories, Illumina, Inc., Genesis GeneticsThermo Fisher Scientific, Inc., Bio-Rad Laboratories Inc., , Agilent Technologies, F. Hoffmann-La Roche Ltd., Counsyl, Inc., ARUP Laboratories. BGI among others.

The report covers exhaustive analysis on:

Regional analysis includes

Report Highlights:

For any queries get in touch with Industry Expert @ https://www.persistencemarketresearch.co/ask-an-expert/31204

The market report addresses the following queries related to the Predictive Genetic Testing market:

The study objectives of Predictive Genetic Testing Market Report are:

To analyze and research the Predictive Genetic Testing market status and future forecast in United States, European Union and China, involving sales, value (revenue), growth rate (CAGR), market share, historical and forecast.

To present the Predictive Genetic Testing manufacturers, presenting the sales, revenue, market share, and recent development for key players.

To split the breakdown data by regions, type, companies and applications

To analyze the global and key regions Predictive Genetic Testing market potential and advantage, opportunity and challenge, restraints and risks.

To identify significant trends, drivers, influence factors in global and regions

To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the Predictive Genetic Testing market.

Request Report Methodology @ https://www.persistencemarketresearch.co/methodology/31204

Read more from the original source:
The Economic Impact of Coronavirus on Predictive Genetic Testing Market Forecasted To Surpass The Value Of US$ XX Mn/Bn By 2065 2019 2029 - Latest...

The report delivers the driving factors, challenges, restraints, opportunities, acquisition & merger, revenue structure, business models, market players, segmentation, regional analysis, production price, manufacturing process, operations, methodology, market share, market size, CAGR, and investments.

Request a sample of this report @ https://www.orbisresearch.com/contacts/request-sample/3856288

Manufacturer Detail

Manufacturer DetailAugury SystemsBosch Software Innovations GmbhC3 IotDell Technologies, Inc.Fluke CorporationGeneral Electric CompanyHitachi, Ltd.Honeywell International, Inc.Ibm CorporationPtcRapidminer, Inc.Rockwell Automation, Inc.Sap SeSas Institute, Inc.Schneider ElectricSenseye, Ltd.SkfSoftware AgSoftweb Solutions, Inc.T-Systems International GmbhWarwick Analytics

BIS reports covers key roles in analyzing the industry outlook and let understand the prominent vendors about their strategies and future plans for the betterment of the market in the near future. Furthermore, the report also covers an ultimate goal of market target gained on the basis of product or services. In this Preimplantation Genetic Testing market report, viewers can also experience detailed study of business introduction including benefits, restraints, opportunities, challenges, drivers, and more. The report smartly takes you to productive methodology in organizing, collection, and analyzing data. The report covers key aspects including production, market share, CAGR, key regions, leading vendors, and revenue rates. This keyword report also provides viewers with relevant figures at which the Preimplantation Genetic Testing market was valued in the base year and estimated to project the revenue in the forecasted period. The Preimplantation Genetic Testing market is categorizes several segmentations including type, application, end user industry, and region. This effective set of information delivers an in-depth analysis about the drivers, challenges, market share, market dynamics, emerging countries, pricing, investment activity, industry performance, revenue generation and CAGR.

Region Segmentation

North America Country (United States, Canada)South AmericaAsia Country (China, Japan, India, Korea)Europe Country (Germany, UK, France, Italy)Other Country (Middle East, Africa, GCC)

Product Type SegmentationPreimplantation Genetic Screening (Pgs)Preimplantation Genetic Diagnosis (Pgs)Industry SegmentationAneuploidyStructural Chromosomal AbnormalitiesSingle Gene DisordersX-Linked DisordersHla Typing

Browse the complete report @ https://www.orbisresearch.com/reports/index/global-preimplantation-genetic-testing-market-report-2019

Channel (Direct Sales, Distributor) Segmentation

Section 8: 400 USDTrend (2019-2024)

Section 9: 300 USDProduct Type Detail

Section 10: 700 USDDownstream Consumer

Section 11: 200 USDCost Structure

Section 12: 500 USDConclusion

The research report is an overall draft when it comes to understand the investment structure and future analysis of the Preimplantation Genetic Testing market. BIS Report manages to convey detailed information regarding prominent vendors of the Preimplantation Genetic Testing market including recent innovations, advancements, improvements, business estimation, revenue margin, and sales graph.

Consumer-wise, the report studies about the demand coming from particular region and category of consumers taking interest in the product or services of the Preimplantation Genetic Testing market. The global keyword market is majorly driven by key factors and offers an in-depth insight about the keyword market.

Make an enquiry of this report @ https://www.orbisresearch.com/contacts/enquiry-before-buying/3856288

The Preimplantation Genetic Testing market reports delivers the information about market competition between vendors through regional segmentation of markets in terms of business opportunities, demand & supply, and revenue generation potential.

BIS report envision clear view about Preimplantation Genetic Testing market including regional growth and falls down mentioning about particular forecast period along with appropriate reasoning about the market.

The Preimplantation Genetic Testing market also delivers the market size, market appearances, segmentation, provincial collapses, tendencies, competitive background to gain the appropriate insights. Moreover, the report also covers about the acquisitions and mergers taken in the recent past.

About Us:

Orbis Research (orbisresearch.com) is a single point aid for all your market research requirements. We have vast database of reports from the leading publishers and authors across the globe. We specialize in delivering customized reports as per the requirements of our clients. We have complete information about our publishers and hence are sure about the accuracy of the industries and verticals of their specialization. This helps our clients to map their needs and we produce the perfect required market research study for our clients.

Contact Us:Hector CostelloSenior Manager Client Engagements4144N Central Expressway,Suite 600, Dallas,Texas 75204, U.S.A.Phone No.: USA: +1 (972)-362-8199 | IND: +91 895 659 5155Email ID: [emailprotected]

See the original post here:
Preimplantation Genetic Testing Industry Analysis, by Services, Key Players, Size, Trends and Forecast 2024 - Latest Herald

Direct-to-Consumer (DTC) Genetic Testing Market 2020 Report analyses the industry status, size, share, trends, growth opportunity, competition landscape and forecast to 2025. This report also provides data on patterns, improvements, target business sectors, limits and advancements. Furthermore, this research report categorizes the market by companies, region, type and end-use industry.

Delivering the key insights pertaining to this industry, the report provides an in-depth analysis of the latest trends, present and future business scenario, market size and share of Major Players such asEasyDNA, Ancestry, 23andMe Inc., Color Genomics, Inc., Genesis HealthCare, Full Genomes Corporation, Inc., Helix OpCo LLC, IDENTIGENE, LLC, Living DNA Ltd, Mapmygenome, Pathway Genomics, Gene by Gene, Ltd., MyHeritage Ltd., 10X Genomics, Dante Labs, Inc., 24Genetics, LabCorp, Myriad Genetics.

Global direct-to-consumer (DTC) genetic testing market is set to witness a healthy CAGR of 18% in the forecast period of 2019-2026.

Get Sample Report: To Know the Impact ofCOVID-19 on this Industry @https://www.databridgemarketresearch.com/request-a-sample/?dbmr=global-direct-to-consumer-dtc-genetic-testing-market

Market Dynamics:

Set of qualitative information that includes PESTEL Analysis, PORTER Five Forces Model, Value Chain Analysis and Macro Economic factors, Regulatory Framework along with Industry Background and Overview.

Global Direct-to-Consumer (DTC) Genetic Testing Research Methodology

Data Bridge Market Research presents a detailed picture of the market by way of study, synthesis, and summation of data from multiple sources.The data thus presented is comprehensive, reliable, and the result of extensive research, both primary and secondary. The analysts have presented the various facets of the market with a particular focus on identifying the key industry influencers.

Major Drivers and Restraints of the Direct-to-Consumer (DTC) Genetic Testing Industry

Market Drivers

High ageing population and growing prevalence of genetic diseases will boost this market growth

Growing customer awareness about the DTC genetic testing acts as a market driver

Tests are effortlessly accessible to the customers around the world; this factor acts as a major market driver

Market Restraints

High charges of DTC genetic testing kits can hamper the growth of this market

Lack of skilled and trained professional is another factor restraining the growth of the market

Scientific, technical and clinical issues along with fidelity to facts and truth-in-advertising can also act as restraining factor for the growth of this market

Complete report is available @https://www.databridgemarketresearch.com/toc/?dbmr=global-direct-to-consumer-dtc-genetic-testing-market

For an excellent outcome of Direct-to-Consumer (DTC) Genetic Testing report, qualitative and transparent research studies are carried out devotedly for the specific niche. Being a global market research report, it also identifies, analyses, and estimates the emerging trends along with major drivers, challenges and opportunities in the industry and analysis of vendors, geographical regions, types, and applications. An idea about competitive landscape plays very important role in deciding about the improvements required in the product and more. As businesses can achieve thorough insights with this report, they can confidently take decisions about their production and marketing strategies.

The titled segments and sub-section of the market are illuminated below:

Region Included are:United States, Europe, China, Japan, Southeast Asia, India & Central & South America

By Service: Diagnostic Screening, Prenatal, Newborn Screening, Pre-Implantation Diagnosis

By Product Type: Ancestry, Health and Wellness, Entertainment

By Business Model: Genome Data Bank Material Model, Individual Health Planning Model

Top Players in the Market are: EasyDNA, Ancestry, 23andMe Inc., Color Genomics, Inc., Genesis HealthCare, Full Genomes Corporation, Inc., Helix OpCo LLC, IDENTIGENE, LLC, Living DNA Ltd, Mapmygenome, Pathway Genomics, Gene by Gene, Ltd., MyHeritage Ltd., 10X Genomics, Dante Labs, Inc., 24Genetics, LabCorp, Myriad Genetics.

How will the report help new companies to plan their investments in the Direct-to-Consumer (DTC) Genetic Testing market?

The Direct-to-Consumer (DTC) Genetic Testing market research report classifies the competitive spectrum of this industry in elaborate detail. The study claims that the competitive reach spans the companies of.

The report also mentions about the details such as the overall remuneration, product sales figures, pricing trends, gross margins, etc.

Information about the sales & distribution area alongside the details of the company, such as company overview, buyer portfolio, product specifications, etc., are provided in the study.

Any query? Enquire Here For Discount Or Report Customization:https://www.databridgemarketresearch.com/inquire-before-buying/?dbmr=global-direct-to-consumer-dtc-genetic-testing-market

Some of the Major Highlights of TOC covers:

Chapter 1: Methodology & Scope

Definition and forecast parameters

Methodology and forecast parameters

Data Sources

Chapter 2: Executive Summary

Business trends

Regional trends

Product trends

End-use trends

Chapter 3: Direct-to-Consumer (DTC) Genetic Testing Industry Insights

Industry segmentation

Industry landscape

Vendor matrix

Technological and innovation landscape

Chapter 4: Direct-to-Consumer (DTC) Genetic Testing Market, By Region

Chapter 5: Company Profile

Business Overview

Financial Data

Product Landscape

Strategic Outlook

SWOT Analysis

Thanks for reading this article, you can also get individual chapter wise section or region wise report version like North America, Europe or Asia.

About Data Bridge Market Research:

An absolute way to forecast what future holds is to comprehend the trend today!Data Bridge set forth itself as an unconventional and neoteric Market research and consulting firm with unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market. Data Bridge endeavors to provide appropriate solutions to the complex business challenges and initiates an effortless decision-making process. Data bridge is an aftermath of sheer wisdom and experience which was formulated and framed in the year 2015 in Pune.

Contact:

Data Bridge Market Research

US: +1 888 387 281

TheGlobal Direct-to-Consumer (DTC) Genetic Testing Marketstudy with 100+ market data Tables, Pie Chat, Graphs & Figures is now released by Data Bridge Market Research. The report presents a complete assessment of the Market covering future trend, current growth factors, attentive opinions, facts, and industry validated market data forecast till 2026. Delivering the key insights pertaining to this industry, the report provides an in-depth analysis of the latest trends, present and future business scenario, market size and share of Major Players such asEasyDNA, Ancestry, 23andMe Inc., Color Genomics, Inc., Genesis HealthCare, Full Genomes Corporation, Inc., Helix OpCo LLC, IDENTIGENE, LLC, Living DNA Ltd, Mapmygenome, Pathway Genomics, Gene by Gene, Ltd., MyHeritage Ltd., 10X Genomics, Dante Labs, Inc., 24Genetics, LabCorp, Myriad Genetics.

Global direct-to-consumer (DTC) genetic testing market is set to witness a healthy CAGR of 18% in the forecast period of 2019-2026.

Get Sample Report: To Know the Impact ofCOVID-19 on this Industry @https://www.databridgemarketresearch.com/request-a-sample/?dbmr=global-direct-to-consumer-dtc-genetic-testing-market

Market Dynamics:

Set of qualitative information that includes PESTEL Analysis, PORTER Five Forces Model, Value Chain Analysis and Macro Economic factors, Regulatory Framework along with Industry Background and Overview.

Global Direct-to-Consumer (DTC) Genetic Testing Research Methodology

Data Bridge Market Research presents a detailed picture of the market by way of study, synthesis, and summation of data from multiple sources.The data thus presented is comprehensive, reliable, and the result of extensive research, both primary and secondary. The analysts have presented the various facets of the market with a particular focus on identifying the key industry influencers.

Major Drivers and Restraints of the Direct-to-Consumer (DTC) Genetic Testing Industry

Market Drivers

High ageing population and growing prevalence of genetic diseases will boost this market growth

Growing customer awareness about the DTC genetic testing acts as a market driver

Tests are effortlessly accessible to the customers around the world; this factor acts as a major market driver

Market Restraints

High charges of DTC genetic testing kits can hamper the growth of this market

Lack of skilled and trained professional is another factor restraining the growth of the market

Scientific, technical and clinical issues along with fidelity to facts and truth-in-advertising can also act as restraining factor for the growth of this market

Complete report is available @https://www.databridgemarketresearch.com/toc/?dbmr=global-direct-to-consumer-dtc-genetic-testing-market

For an excellent outcome of Direct-to-Consumer (DTC) Genetic Testing report, qualitative and transparent research studies are carried out devotedly for the specific niche. Being a global market research report, it also identifies, analyses, and estimates the emerging trends along with major drivers, challenges and opportunities in the industry and analysis of vendors, geographical regions, types, and applications. An idea about competitive landscape plays very important role in deciding about the improvements required in the product and more. As businesses can achieve thorough insights with this report, they can confidently take decisions about their production and marketing strategies.

The titled segments and sub-section of the market are illuminated below:

Region Included are:United States, Europe, China, Japan, Southeast Asia, India & Central & South America

By Service: Diagnostic Screening, Prenatal, Newborn Screening, Pre-Implantation Diagnosis

By Product Type: Ancestry, Health and Wellness, Entertainment

By Business Model: Genome Data Bank Material Model, Individual Health Planning Model

Top Players in the Market are: EasyDNA, Ancestry, 23andMe Inc., Color Genomics, Inc., Genesis HealthCare, Full Genomes Corporation, Inc., Helix OpCo LLC, IDENTIGENE, LLC, Living DNA Ltd, Mapmygenome, Pathway Genomics, Gene by Gene, Ltd., MyHeritage Ltd., 10X Genomics, Dante Labs, Inc., 24Genetics, LabCorp, Myriad Genetics.

How will the report help new companies to plan their investments in the Direct-to-Consumer (DTC) Genetic Testing market?

The Direct-to-Consumer (DTC) Genetic Testing market research report classifies the competitive spectrum of this industry in elaborate detail. The study claims that the competitive reach spans the companies of.

The report also mentions about the details such as the overall remuneration, product sales figures, pricing trends, gross margins, etc.

Information about the sales & distribution area alongside the details of the company, such as company overview, buyer portfolio, product specifications, etc., are provided in the study.

Any query? Enquire Here For Discount Or Report Customization:https://www.databridgemarketresearch.com/inquire-before-buying/?dbmr=global-direct-to-consumer-dtc-genetic-testing-market

Some of the Major Highlights of TOC covers:

Chapter 1: Methodology & Scope

Definition and forecast parameters

Methodology and forecast parameters

Data Sources

Chapter 2: Executive Summary

Business trends

Regional trends

Product trends

End-use trends

Visit link:
Direct-to-Consumer (DTC) Genetic Testing Market (COVID-19 Impact Analysis)2020 Global Industry Analysis, Size, Growth, Trends, Share and Forecast...

As the tab for security incidents in 2020 remains open, cybercriminals are diligently looking for new ways to attack and capitalize on valuable healthcare information. More than 143 security incidents have been added to the Health Insurance Portability and Accountability Act (HIPAA) Breach Reporting Tool since the beginning of the year, and bad actors are not showing signs of halting their disruptive actions any time soon.

Last months showstopper is Ambry Genetics, a California-based genetic testing laboratory that revealed a security incident potentially exposing the personal health information (PHI) of 233,000 customers, including:

Customer names Medical information Information related to customers use of the genetic laboratorys services Limited amount of Social Security numbers

In accordance with HIPPA Breach Notification Rule, the company has published a notice on its official page, detailing the events. Between 22 and 24 January, Ambrys security team noticed unauthorized access to one of their employee accounts and started investigating the incident. Although the company found no clear signs of misuse, it does not rule out the exposure of customer personal information.

The investigation was unable to determine whether there was unauthorized access to, or acquisition of, any particular information from the email account, and we are not aware of any misuse of any personal information. Nevertheless, we are notifying our customers because customer personal information may have been impacted, reads the Substitute Notice.

As a preventive measure, Ambry Genetics is now offering customers free identity monitoring services to affected individuals and reassures customers that they have taken the necessary steps to avoid any future incidents.

The high number of potentially exposed medical records put customers at risk of falling victim to medical identity theft and fraud. Using the stolen information, cyber thieves can make fake medical claims and steal a victims insurance, and even send out extortion emails that demand payment for not revealing any sensitive information.

Its important for potential victims to be wary of any unsolicited emails they might find in the Inbox, keep an eye on their medical bills, and review their medical records for any suspicious entries.

Recent Articles By Author

*** This is a Security Bloggers Network syndicated blog from HOTforSecurity authored by Alina Bizga. Read the original post at: https://hotforsecurity.bitdefender.com/blog/medical-information-of-233000-individuals-exposed-after-genetic-testing-lab-hack-23097.html

More here:
Medical Information of 233,000 Individuals Exposed after Genetic Testing Lab Hack - Security Boulevard

What happened

Shares of genetic-testing companyInvitae (NYSE:NVTA) rose over 13% today on an upbeat day for the stock market. The S&P 500 rose over 1.5% as investors cheered plans by some countries and U.S. states to soon begin reopening parts of their economies.

While the broad economic damage caused by the coronavirus pandemic might take quarters or years to repair, the genetic testing industry might experience a faster recovery. That's because strict stay-at-home orders are negatively impacting the number of genetic tests and diagnostics ordered by doctors. But if restrictions are loosened in the coming weeks or months, then doctors should be able to resume certain types of essential services, such as hereditary tests for pregnant women or oncology testing for cancer patients.

As of 3:15 p.m. EDT, the growth stock had settled to a 8.4% gain.

Image source: Getty Images.

Invitae hasn't publicly commented on how the coronavirus pandemic has impacted operations, but investors can likely expect at least a short-term drop. Peer NeoGenomics reported a 20% decline in test volumes in the final two weeks of March and in early April, compared with the year-ago period.

NeoGenomics focuses exclusively on cancer diagnostics, whereas Invitae offers tests for a wide variety of health conditions. If stay-at-home decrees caused more-significant declines in orders for nonessential genetic tests (such as for rare diseases and hereditary risks) than for essential genetic tests (such as cancer monitoring), then investors might expect Invitae to have suffered a greater decline in test volumes and revenue than NeoGenomics.

Invitae is scheduled to report first-quarter 2020 earnings and update its outlook on May 5. A temporary slowdown in growth might not matter much in the long run, but a growth-at-all-costs business model doesn't leave the company well positioned to endure a prolonged economic rut. Investors will need to await further details before lazily assuming the business will be spared.

Here is the original post:
Here's Why Invitae Stock Popped as Much as 13.2% Today - The Motley Fool

BOSTON, April 28, 2020 /PRNewswire/ -- In their brand new report "COVID-19 Diagnostics", global market research firm IDTechEx benchmarked more than 100 commercial devices across various technologies, providing a deep insight into the technology trends and biotech innovations surrounding the COVID-19 global response. For more information on this report, please visit http://www.IDTechEx.com/COVID.

Fighting the COVID-19 fire with molecular diagnostics innovations, technologies benchmarked in the new report from IDTechEx COVID-19 Diagnostics (www.IDTechEx.com/COVID)

"You cannot fight a fire blindfolded. And we cannot stop this pandemic if we don't know who is infected. We have a simple message for all countries: test, test, test. Test every suspected case" - Dr Tedros Adhanom Ghebreyesus, Director-General, World Health Organization (WHO).

Viruses were once known as "contagious living fluids", strange infectious substances capable of slipping through the finest of filters unnoticed. SARS-CoV-2, the coronavirus responsible for the COVID-19 pandemic is indeed slipping through every layer of society, leaving behind severe public health and economic crises. Unlike in the influenza pandemic in 1918, today we are better equipped to identify the elusive bug.

Since the full genome sequencing of the SARS-CoV-2, many national laboratories have identified the regions of the genome amenable for genetic testing. The golden standard adopted by national laboratories around the world following the WHO protocol to detect the virus in individuals, is based on detecting genetic material specific to SARS-CoV-2 viruses in a person's nasopharyngeal secretions. The main tool for such genetic tests is the Reverse Transcription Polymerase Chain Reaction (RT-PCR). Primer strands that hybridise specifically to the SARS-CoV-2 genome, together with fluorescent probes, help amplify and detect the viral load present in a patient. RT-PCR, normally performed in a real-time quantitative qRT-PCR machine for live fluorescent read-out, constitutes the core element of the testing effort being deployed at the moment across the globe. Clinical laboratories with the necessary equipment and technical know-how to perform RT-PCR are leading this diagnosis effort.

However, not all countries are prepared, neither logistically or with enough equipment and capacity. An important bottleneck is the short supply of certain ancillary reagents, such as RNA extraction kits. The shortage of such supplies and long processing time, has led to many laboratories to try to circumvent some steps in the protocol and to come up with new approaches to reach the testing targets that have been set by policymakers and healthcare officials.

The need for universal and massive testing across the population has led to a race for technology innovations for COVID-19 diagnostics. Point-of-care molecular diagnostics (POC MDx) are portable devices that perform molecular diagnosis away from central labs. Microfluidics is the key technology behind POC MDx, which controls the motion of small amounts of fluids in microchannels. Microfluidic cartridges enable the miniaturisation of devices and introduces automation in the sample handling and detection processes. Some POC MDx devices use isothermal amplification of nucleic acid as an alternative to PCR devices. Isothermal amplifaction bypasses the need of thermal cycling and reduces the detection time to just 5 min. Various isothermal amplifaction methods have been adopted for COVID-19 diagnostics. Complex design and unspecific amplification hinder the widespread use of this method. "COVID-19 Diagnostics" provides a deep insight and comparison into the technologies, innovations and current progress on POC MDx and isothermal amplification.

Story continues

Apart from the time consuming thermal cycling, real-time fluorescent detection is another limitation for low-cost and portable diagnosis tools. Lateral flow assays, electrochemical detection and microbead-based arrays are integrated with PCR to detect the amplified genetic products. These hybrid systems enable faster, cheaper and palm-size devices at the expense of sensitivity and specificity. More recently, CRISPR-Cas (gene-editing tool based on speficifc gene recognition) and DNA sequencing techniques show the potential for highly sensitive and selective hybrid systems, as highlighted in "COVID-19 Diagnostics". For more information on this report, please visit http://www.IDTechEx.com/COVID or for the full portfolio of medical technology research available from IDTechEx please visit http://www.IDTechEx.com/LifeSci.

Resonating with the message of the WHO director general: "test, test and test", these innovations offer the tools to stop the current outbreak, as well as to prevent future outbreaks, by effective diagnostics and surveillance testing.

IDTechEx guides your strategic business decisions through its Research, Consultancy and Event products, helping you profit from emerging technologies. For more information on IDTechEx Research and Consultancy, contact research@IDTechEx.com or visit http://www.IDTechEx.com.

Media Contact:Jessica AbineriMarketing Coordinator press@IDTechEx.com+44(0)1223-812300

View original content to download multimedia:http://www.prnewswire.com/news-releases/fighting-the-covid-19-fire-with-molecular-diagnostics-new-idtechex-report-on-innovations-301048428.html

SOURCE IDTechEx

Read the rest here:
Fighting The COVID-19 Fire With Molecular Diagnostics, New IDTechEx Report on Innovations - Yahoo Finance

Mastermind Genomic Search Engine Identifies Approved and Off-Label Treatments Found Across the Medical Literature

ANN ARBOR, Mich. (PRWEB) April 28, 2020

Genomenon announced today that the latest release of the Mastermind Genomic Search Engine includes the ability to search by therapy. Mastermind users can now query the comprehensive database of genomic evidence for over 180,000 drugs, therapies, and other interventions.

This new offering furthers Genomenon's ability to catalogue a complete dataset of all "Genomic Associations" supported by medical evidence. These associations help clinical labs more accurately and rapidly diagnose patients, and pharmaceutical companies make ground-breaking discoveries in the effective treatment cancer and other genetic diseases. Mastermind was launched in 2017 with the ability to uncover associations between diseases, genes, and variants, and has since added ACMG/AMP classification, phenotypes, and now therapies. Each new component of association data increases the power of Mastermind to allow users to find genetic evidence, test or generate hypotheses, and draw clinical conclusions with confidence.

Searching by therapy provides significant value for oncologists making decisions on third-line therapies, where approved drugs or clinical trials are no longer effective for a cancer patient. Finding a comprehensive list of all therapies in the medical research tied to a cancer patient's genetic make-up is invaluable for treating these late-stage cancer patients.

The new search capability is also highly useful for clinicians making diagnostic and treatment decisions for patients with rare diseases. There are currently less than 800 FDA approved therapies for over 7,000 rare diseases, leaving many patients without an approved treatment option. In these cases, clinicians are required to scour the medical literature to find therapies associated with the patient's genetic profile; a time-consuming and often fruitless task.

About Genomenon

Genomenon is a genomic health IT company that connects patient DNA with the billions of dollars spent on research to help doctors diagnose and cure cancer patients and babies with rare diseases.

The Mastermind Genomic Search Engine is used by hundreds of genetic labs worldwide to accelerate diagnosis, increase diagnostic yield, and assure repeatability in reporting genetic testing results.

Mastermind Genomic Landscapes inform pharmaceutical and bio-pharma companies on precision medicine development, deliver genomic biomarkers for clinical trial target selection, and support CDx regulatory submissions with empirical evidence.

Genomenon was named 2020 Global Company of the Year in Clinical Genomics Interpretation by Frost & Sullivan.

For more information, visit Genomenon.com.

For the original version on PRWeb visit: https://www.prweb.com/releases/genomenons_mastermind_now_finds_therapies_associated_with_genetic_drivers/prweb17078524.htm

Continued here:
Genomenon's Mastermind Now Finds Therapies Associated with Genetic Drivers - Benzinga

Seeking ways to uncover new customer applications in the biomedical field led Japanese multinational imaging and electronics company, Ricoh, to develop a proprietary bioprinting technology that is now being used to control DNA molecule-by-molecule to accurately detect trace amounts of virus in genetic testing. More particularly, this is being done in polymerase chain reaction (PCR) testing, a tool used for medical testing which has become a familiar household name around the world ever since the COVID-19 pandemic began.

Ricoh will now be marketing their newly developed Ricoh Standard DNA Series as reference material for genetic testing applications where PCR is used, to overcome challenges in PCR testing. The Standard DNA Series enables a specific number of DNA molecules, in units of one, to be injected into containers used for genetic testing applications, which according to the company, means that the accuracy of detection in PCR tests can be assured even in low concentrations of under 100 molecules.

The PCR high-performance genetic testing method invented in 1985 by Kary B. Mullis can detect all types of bacteria, parasites, viruses, and fungi, starting with DNA or RNA by selectively amplifying trace amounts of genetic material, identifying specific parts of the DNA. It can potentially detect DNA even at the level of a single molecule by amplifying it. However, Ricoh indicated that, in reality, extremely small amounts of DNA cannot be detected in some tests because of inadequate precision control in the apparatus or imperfect performance and quality of reagents, leading to false negatives, where viruses cannot be detected even though the person is infected, and this makes accurate diagnosis of viral diseases challenging.

In fact, scientists in the US have warned that there is a growing concern from the over-reliance of COVID-19 testing since the majority of the tests around the world use PCR technology to detect traces of the coronavirus in mucus samples, and these are not 100 percent reliable.

Evaluation of reference DNA plate for the novel coronavirus SARS-CoV-2 by real-time PCR*3 (Credit: Ricoh)

By leveraging its bioprinting technology, Ricoh has created new value through innovation. In fact, the company has now expanded the use of this product by developing reference DNA plates for specific types of viruses, including the novel coronavirus SARS-CoV-2, instead of just supplying reference DNA plates for noroviruses one of most common viral causes of gastroenteritis. For now, these plates are only available in Japan.

Ricoh suggested that the accuracy of PCR tests is determined by their sensitivity and specificity. Sensitivity refers to the proportion of cases in which people infected with the virus (true positives) are correctly identified as positive. Specificity refers to the proportion of cases in which people who are not infected with the virus (true negatives) are correctly identified as negative. They claim that one of the reasons for inaccurate detection may be insufficient verification of the sensitivity and specificity of the PCR test. In addition, there are detection limits with PCR testing when trace amounts of a virus below a certain limit cannot be detected. In the event a sample has a viral level below the detection limit at the time of the test, the result of the PCR test will be negative, even if the virus is present in the sample, and consequently, the result will be a false negative and can lead to new infections because patients carry out daily activities without realizing they are infected. Reducing false negatives can contribute to reducing the risk of infection spreading.

To verify the detection limit and the sensitivity of PCR testing, and to accurately measure and control the performance and quality of test instruments and reagents, it is necessary to use reference material where the number of DNA molecules is specified accurately as a standard in the test. Reference materials for genetic tests have already been supplied by several companies and research institutes, but they are highly concentrated materials and even though high-concentrations are ok, it has been difficult with low-concentrations of less than 100 molecules to judge whether or not the measurement is accurate.

Solving this problem in PCR testing has been achieved by Ricoh. They claim that their product uses bioprinting technology with a unique inkjet method to dispense DNA molecules into the wells of plates or tubes for genetic testing in units. This means that there is no variation in the number of DNA molecules, even at low concentrations, and it makes it possible to exercise strict precision control and quality control over genetic testing methods, testing devices, and reagents. The number of DNA molecules injected per well can also be increased incrementally as required.

According to Ricoh, in order to precisely verify genetic tests, devices, and reagents, researchers need a scale or benchmark in which the number of DNA molecules is determined. Through joint research, Ricoh has developed a technology to manufacture a container of a prescribed number of DNA molecules, called a reference DNA plate. And because the number of DNA molecules is accurately controlled molecule-by-molecule, the technology will enable stricter quality control of genetic testers, reagents, and genetic testing methods as well as increase the reliability of genetic tests.

Headquartered in Tokyo, where the company operates its proprietary 3D bioprinter technology, Ricoh will begin marketing its newly developed Ricoh Standard DNA Series as reference material for genetic testing applications where PCR is used.

In the future, Ricoh hopes to expand the applications of the Ricoh Standard DNA Series to precision control of genetic testing methods and reagents, to handle unknown infectious diseases and contribute to virus-free tests (tests that certify the absence of viruses) used in the manufacture of regenerative medicines and biopharmaceuticals.

As more companies begin to flood the biomedical field, aiding with research, leveraging bioprinting technology, and creating new venues for institutes and laboratories to expand their innovation, new and dedicated applications and discoveries help the industry advance quicker than ever before. Hopefully, widely recognized changes, like Ricohs new development and move into the bioprinting realm, will engage more companies to transform their technology and invest in bioengineering, life sciences, and other industries of the future, which are elemental to our survival.

The rest is here:
Ricohs Bioprinting Technology Could Help Improve PCR Testing - 3DPrint.com

The first baby bison of the season was born on April 28. Photo: Michael Pfaff, Fermilab

On April 28, baby bison season officially began. The first calf of the year was born in the late morning, and mother and baby are doing well.

Fermilab is expecting between 12 and 14 new calves this spring.

Fermilabs first director, Robert Wilson, established the bison herd in 1969 as a symbol of the history of the Midwestern prairie and the laboratorys pioneering research at the frontiers of particle physics.

And thanks to the science of genetic testing, Fermilab has confirmed that the laboratorys herd shows no evidence of cattle gene mixing. Farmers during the early settlement era would breed bison with cattle in an attempt to create more tame bison or more hardy cattle.

A herd of bison is a natural fit for a laboratory surrounded by nature. Fermilab hosts nearly 1,000 acres of reconstructed tallgrass prairie, as well as remnant oak savannas, marshes and forests.

To learn more about Fermilabs bison herd, please visit the section onwildlife at Fermilab on our website.

The entire Fermilab site in Batavia is closed to the general public at this time, so visits to view the bison are not currently possible. Updates will be posted on the Visit Fermilab webpage. Learn more about Fermilabs science and people by following Fermilabs social media pages @Fermilab.

The Fermilab site has been designated a National Environmental Research Park by the U.S. Department of Energy. The labs environmental stewardship efforts are supported by the Department of Energy Office of Science as well as Fermilab Natural Areas.

Fermilab is supported by the Office of Science of the U.S. Department of Energy. The Office of Science is the single largest supporter of basic research in the physical sciences in the United States and is working to address some of the most pressing challenges of our time. For more information, visit science.energy.gov.

Go here to see the original:
First baby bison of the year born at Fermilab - Fermi National Accelerator Laboratory

Representational Image

Sunshine and summer may ebb the spread of the coronavirus, and BCG vaccine (already given to all Indians) also may offer partial immunity, says Ravi Godse, Director of Discharge Planning, UPMC Shadyside Pennsylvania, the US. Godse recommended the use of plasma therapy for serious patients in an email interview with IANS.

Here are the excerpts fro the interview:

Recently, the White House said the spread of coronavirus may ebb during summer months. May and June will have peak summers in most parts of the country, do you think high temperatures will help in containing the outbreak?

Viral illnesses tend to go away in the summer months. This trend is more distinct in countries like America where there are distinct weather patterns with brutally cold winters (in most states) and warm summers. While social activity in the summer often involves outdoor spaces, winter activities tend to be more congested and indoors.

In the summer, the humidity can go up as well, meaning more water drops in the air. If the air is saturated with water and somebody sneezes virus droplets into such air, it is likely that the droplets will fall to the ground quicker, making them less infectious. So the short answer is yes, summer/sunshine could be better. We know what we know, but we don't know what we don't know.

Recently, the health minister said the efforts to contain the outbreak, has saved India from going into Stage 3 or community transmission stage, and many senior officials said the COVID-19 disease is under control. With 20,177, active cases in the country, do you think things are under control?

India is a big and populous country and will likely behave similar to America (though India has fewer foreign travelers). In America, San Francisco is very different from Indianapolis; New York is different from Las Vegas. Similarly, Agartala is different from Mumbai and Chennai is different from Shimla. So India will behave as if individual states are different nations.

Some people think that India is 4 weeks behind America in the peak. But India's lockdown (March 24) started eight days after that of America (March 16), so India might have had a 3-week head-start on social distancing, and that will help.

It is possible that the BCG vaccine (already given to all Indians) may offer partial immunity. Weather might help. Many people think that the sturdy genes of our population, hardened through experience with infectious illnesses, may afford a more robust cross immunity. This might be more wishful thinking, however, it does seem like India will avert the disastrous peak that other countries experienced. If the cases pick up, then the rest of the world (especially America, which would be far beyond its own peak) would rush to India's help. I don't think that the people of America will soon forget India's selfless and helpful actions regarding hydroxychloroquine.

What is your reaction on plasma therapy?

Use plasma for serious patients. Start collecting the plasma today, if we need it in 3 weeks. Rather than troubling the recovered patients for the plasma, we can try and see if the antibody titer of the healthy asymptotic patients is better (They did better than the patients who ended up in the hospital).

If no relapses occur and there is no drastic increase in the number of cases in July, would it be good enough to declare a major success against COVID-19?

Relapse can be talked in the context of happening in a recovered patient or in the community.

When a patient gets infected, he or she first develops IgM, then IgG antibodies. In some viral illnesses (say chicken pox) the protection could be lifelong. We don't know how long the IgG protection for COVID-19 will last in recovered patients. If it is durable, then relapses should not occur. Even if there is an overall increase in the number of cases of really sick people, the increase would happen gradually over a longer duration, ensuring that the health systems are not overwhelmed and the demand for heath care is spread out. If that happens, we can declare a major success.

We have limited experience on this viral infection. Under these circumstances, can we say people will develop lasting antibodies to protect them from this infection?

We will only know by testing. The antibody testing will be a tool, and it needs to be employed regardless of the cost. If people who have IgG against the virus are shown to be immune from future/recurrent disease, then those people can be used to open the nation and restart the economy. Remember, the vaccine is also coming, which will try and artificially induce lasting antibodies. The challenge could be the fact that novel coronavirus is an RNA virus and can mutate, but remember, not all change is bad: it could become milder or less infectious.

There are many uncertainties with COVID-19one big uncertainty is whether people can be reinfected with the virus. Anecdotal evidence appears to suggest they can. What is the time period within which we could get a vaccine? And after this vaccine, can we say, war has been won against coronavirus?

For us to know that people are getting re-infected, we need to reliably know that they were infected in the first place. What if the first test the person took was a false positive? There is enough scope for confusion. If a person tests positive for a genetic test, then tests negative, and then tests positive again, and you include the possibility of error in any of the 3 tests that the person took, you really won't know. And we are talking only about molecular/genetic tests (that directly measure the virus) so far. What happens to error when we introduce the antibody test (that measures the body's response to a virus)?

My thinking is simple, if a patient is mildly symptomatic, he/she does not need the test. Assume the disease is there and behave accordingly. A good 90 per cent of people diagnosed with COVID-19 will likely be okay, 5 per cent will be very sick and get better, and 5 per cent may die. But remember, if for every diagnosed patient, there are 1000 asymptomatic patients walking about, then the case rate is high, but the mortality rate should also be divided by 1000 and would be 0.005 per cent.

A vaccine will likely come and sooner than we think. There are multiple drugs that are being tried to cut the severity of the illness.

In the US, pediatricians say 80 per cent of the kids are likely to have coronavirus, but they are so asymptomatic one would not come to know. What is your view in the Indian context, are children vulnerable here too?

Yes. However, we should note that the US is not genetically homogenous. It is not a race, per say. It is a teeming nation of nations, packed with people from various gene pools, like Walt Whitman said. India is more homogenous. But my belief is that Indian kids will behave more like American kids.

Also, I saw reports that suggest 80 percent people in Mumbai might be asymptomatic. Then, kids will be behaving like adults in more ways than one!

What are your suggestions on tackling COVID-19?

Isolate and quarantine mildly symptomatic patients. Try and use experimental drugs to keep moderately symptomatic patients from getting serious. Keep waiting for the vaccine, hoping for it is early and effective, and preparing for it being neither. Find the most accurate antibody test and use it by the thousands. Confirm by genetic testing on random samples to see if these people are getting reinfected. If they are not, release these antibody positive patients into the work force and open the economy and life itself. Finally, the discussion regarding opening up needs to start now. It needs to effectively communicate the goals, how they will be achieved, with firm dates, with the capacity to adjust without panicking, if the cases pick up after the lockdown is lifted.

See the rest here:
Indians May Be Partially Immune to COVID-19 Due to BCG Vaccine, Says US-Based Expert - The Weather Channel

Ah, spring! The dogwoods are in bloom. What a glorious time it is to be in Virginia.

Except for one thing.

The powers that be have decided to upend everything we once held dear deciding they can just change even the most basic facts willy-nilly simply to satisfy their own agendas. The General Assembly? Oh, heavens no. Were not talking about that. Were talking Congress. Not that Congress, though. This one: The International Botanical Congress.

See you didnt even know there was such a thing, did you? And yet this obscure body of unelected elitists has decided to reach out from its ivory tower and undermine the very foundations of Virginia law. OK, these are scientists botanists, to be precise so what some call elitism others might call merit and expertise. You could have been a scientist, too, if you hadnt sloughed off their science fair project back in seventh grade. And by ivory tower we really mean laboratories and the great outdoors. Anyway, never mind about all that. The point here is that International Botanical Congress has decided to reclassify a whole lot of plants and change their scientific names including, yes, our beloved state tree and state flower, the dogwood.

By state law, its the Cornus florida. But the International Botanical Congress without a single public opinion poll, without a single town hall meeting on CNN, without even so much as an appearance on Fox and Friends has unilaterally renamed it Benthamidia florida.

Does this mean we even have an official state tree and state flower anymore? Is this a loophole that some slick-talking lawyer backed by some well-heeled special interest group can use to make the case that we are now treeless and flowerless and we should elevate some other flora instead? Cry havoc and let slip the dog(wood)s of war!

Umm, no. So much for our alarmist warnings. Maybe we should save those for that other Congress in Washington. The International Botanical Congress actually made this change nine years ago at its 2011 meeting in Melbourne, Australia. Yes, were a little late in bringing you this breaking news. If you wanted on-the-spot coverage, please tell our corporate masters they should have approved our travel request. Your subscription price pays for reporters to watchdog city councils and school boards and the state Legislature but apparently doesnt cover junkets to Down Under for editorial writers who have a bur under their cushy, ergonomically appropriate chair. Yes, were outraged, too. Oh, that bur in question would be an Arctium minus.

But back to our main point: Why did the International Botanical Congress make what the National Center for Biotechnology Information calls sweeping changes to the way scientists name new plants, algae, and fungi? The short answer this will suffice for a family newspaper but not a term paper is that genetic testing has shown that some plants arent related to others the way we once thought they were. Remember when your cousin gave everyone in the family those 23andMe genetic tests for Christmas, and it turns out there were some family secrets that would have been better kept secret? Yeah, sort of like that, only with plants. Hey, we dont judge. But, by golly, the botanists sure do. At the 2011 convention in Melbourne, they reclassified a bunch of plants. This was not without controversy. The debate over the genus Acacia became known as the wattle wars a sometimes acrimonious dispute between American, African and Australian scientists over which continents species would still be considered Acacia when the genus was subdivided into five different ones. The Australians won. The website Scientific Gems tells us that Wikipedia ran a campaign against the official decision for several years yet another reason why you shouldnt be quoting Wikipedia in your homework.

Jordan Metzgar, curator of the Massey Herbarium at Virginia Tech, was at the Melbourne conference to present his research on boreal ferns. As for our beloved dogwood, he tells us what we want to hear: I believe Cornus florida is still appropriate to use.

How can that be? Heres how: Unlike the Congress in Washington, the International Botanical Congress doesnt pass actual laws. Instead it makes suggestions. Its all kind of decentralized, Metzgar says. Connecticut College published an official revision of which names it would use, adopting the new ones. However, many scientists still use the Cornus florida name when referring to dogwoods including the website Flora of Virginia and the Digital Atlas of the Virginia Flora. If Connecticut wants to call the dogwood Benthamidia florida, well, just think of it the way the North and South called the same Civil War battle by different names. What was the Battle of Bull Run in the northern press was the Battle of Manassas in the South. Maybe someday the consensus will shift and well start using Benthamidia as the genus name for our flowering dogwood, but that day hasnt come yet, Metzgar says. To paraphrase other disputes, that will happen when you pry the dogwood out of our cold, dead fingers.

We Virginians love our dogwood, whatever the botanists call it in Latin. We have the Charlottesville Dogwood Festival and the Vinton Dogwood Festival (or at least did, just not this year). Richmond has an outdoor amphitheater called Dogwood Dell. One of our official state songs (yes, we now have more than one) name-checks dogwoods. Sweet Virginia Breeze by Steve Bassett and Robbin Thompson credits the Almighty Himself: Because he must have been thinking about me / when He planted that very first dogwood tree. We love dogwoods so much we make it do double duty as both our state flower and our state tree. The only other state to do this is Mississippi with the magnolia.

To be sure, others love the dogwood, too. Its also the state tree in Missouri, although we made it ours first, and Missouri doesnt love the dogwood enough to make it the state flower, as well. The hawthorn lobby is apparently strong there. Curiously, the dogwood is the state flower in North Carolina, but the pine is the state tree. See? We love you more.

Theres history behind the dogwood, too. The famous cherry trees that Japan gave the U.S. in 1912 that now bloom so brightly in Washington? The U.S. gave Japan 40 dogwoods in return. Alas, all but one died. Perhaps they were simply homesick. Thats what we think anyway. Thats our story, and were sticking to it. In Cornus florida we trust.

Read the rest here:
Their View: Cry havoc and let slip the dog(wood)s of war - Bristol Herald Courier

DUBLIN--(BUSINESS WIRE)--The "Food Pathogen Detection Technology Markets, 2020-2030: COVID-19 Impact and Recovery" report has been added to ResearchAndMarkets.com's offering.

The global food pathogen detection technology market is expected to decline from $10.9 billion in 2019 to $10.3 billion in 2020 at a compound annual growth rate (CAGR) of -5%. The decline is mainly due to the focus on COVID-19 outbreak and its treatment across the globe, while government imposes restrictions on other sectors to operate their processes in full capacity.

The market growth is expected to increase post COVID-19 due to an increased focus on hygiene and good manufacturing practices and manufacturers complying with food safety norms. The market is expected to recover and reach $13.1 billion in 2023 at a CAGR of 4.8%.

Increase in the outbreak of foodborne illness across the world contributed to the growth of the food pathogen detection technology market. According to a report published by WHO in 2018, almost every tenth person falls ill due to pathogens every year and 33 million of healthy life are lost due to foodborne diseases. Diarrhoea is the most common disease caused by contaminated food and almost 550 million people (including 220 million children under 5 years of age) are affected by diarrhoeal diseases. The upsurge in the occurrence of foodborne diseases among the global population increased the demand for food pathogen detection technology driving the market's growth.

Lack of food control infrastructure in developing countries is a major restraint on the food pathogen detection technology market. Food control infrastructure in many developing countries is generally inadequate due to limited resources and poor management. Food control laboratories are often not well equipped and do not have trained staff. Food control systems also face poorly developed compliance guidelines in many developing countries.

Genetic testing technology is being increasingly used for the rapid, sensitive, reliable detection of pathogens on the food. Genetic testing techniques identify the problem even when the pathogens are just formed or are in tiny concentration. For instance, in 2018, LexaGene Holdings Inc., a US-based research and biotechnology company, launched the LX6 analyzer. The LX6 is an automated pathogen detection platform based on genetic testing technology that is used to detect pathogens in food and water in less time and low cost. LX6 has the capability to check for 22 different contaminants in water and food including 2 species of vibrio, 3 species of salmonella, 4 species of shigella, and 2 species of e. coli. The companies in the food pathogen detection technology are investing in the development of new technologies such as genetic technology to enable fast and efficient detection of pathogens.

In February 2019, bioMerieux acquired Invisible Sentinel, a US-based food testing firm for a deal amount of $75 million. The deal is expected to bring innovative solutions to ensure food and beverage quality and to strengthen bioMerieux's position in food pathogen testing and spoilage organism detection. Invisible Sentinel is a US-based firm involved in providing DNA contamination tools for the food, beer, and wine industries.

The food pathogen detection technology market has been geographically segmented into North America, Western Europe, Asia-Pacific, Eastern Europe, South America and Middle East & Africa. Asia-Pacific is expected to grow fastest in the forecast period.

Major players in the food pathogen detection technology market are SGS, Bureau Veritas, Intertek Group, Eurofins Scientific, Silliker, IFP Institut Fr Produktqualitt GmbH, ALS Limited, Asurequality, Microbac Laboratories, and Genetic ID NA.

Key Topics Covered

1. Executive Summary

2. Food Pathogen Detection Technology Market Characteristics

3. Food Pathogen Detection Technology Market Size And Growth

3.1. Global Food Pathogen Detection Technology Historic Market, 2015-2019, $ Billion

3.1.1. Drivers Of The Market

3.1.2. Restraints On The Market

3.2. Global Food Pathogen Detection Technology Forecast Market, 2019-2023F, 2025F, 2030F, $ Billion

3.2.1. Drivers Of The Market

3.2.2. Restraints On the Market

4. Food Pathogen Detection Technology Market Segmentation

4.1. Global Food Pathogen Detection Technology Market, Segmentation By Technology, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

4.2. Global Food Pathogen Detection Technology Market, Segmentation By Food Type, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

4.3. Global Food Pathogen Detection Technology Market, Segmentation By Type, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

5. Food Pathogen Detection Technology Market Regional And Country Analysis

5.1. Global Food Pathogen Detection Technology Market, Split By Region, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

5.2. Global Food Pathogen Detection Technology Market, Split By Country, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

Companies Mentioned

For more information about this report visit https://www.researchandmarkets.com/r/kbpc1w

Visit link:
Food Pathogen Detection Technology Markets, 2020-2030: COVID-19 Impact and Recovery - ResearchAndMarkets.com - Business Wire

Mitochondrial Disorders Genetic Testing: Regional and Global Market Opportunities Key Competitors, Industry Segments, and Strategic Analysis, 2020-2025

The market study is primarily based on primary and secondary data collected through systematic research approach. The research approach is defined by expert market analysts in line with business consultants and international research standards. Economic, political, and environmental regulations for Mitochondrial Disorders Genetic Testing market are examined to draw the conclusion on macroeconomic business environment. The market study also emphasizes on Industry progress in terms of technology, product distribution, product development, and raw material sourcing. The industry attractiveness analysis for different products and applications is explained with appropriate examples. Primary activities and support activities involved in Mitochondrial Disorders Genetic Testing market are discussed to get comprehensive outlook on industry value chain. Major strategic decisions and future business plans of key industry participants are discussed in this market study to interpret Mitochondrial Disorders Genetic Testing industry competition in the coming years.

Request Free Sample Report at:http://www.marketresearchstore.com/report/global-mitochondrial-disorders-genetic-testing-industry-market-2019-684945#RequestSample

Key market players across the global Mitochondrial Disorders Genetic Testing market include Agilent Technologies, Inc., Ariosa Diagnostics, Inc, Illumina, Inc, Sequenom, Inc, LifeCodexx, Laboratory Corporation of America Holdings, PerkinElmer, Inc, Cenata, Natera, Inc, Bio-Rad Laboratories, Inc etc. The high profile companies in Mitochondrial Disorders Genetic Testing market are dedicated to product improvement, value added production, advanced manufacturing facilities and premium product offerings in order to appeal the business on an international level that exhibits the potentials customer base. The market also encompasses international brands functioning through a robust distribution network across diversified markets.

Segment & Regional Analysis

This market study fragments the global market for Mitochondrial Disorders Genetic Testing based on key product types, applications, and regions. The global market for Mitochondrial Disorders Genetic Testing has been divided based on product type as Polymerase Chain Reaction (PCR), Fluorescence In-Situ Hybridization (FISH), Array-Comparative Genomic Hybridization (aCGH). Based on application types, the Mitochondrial Disorders Genetic Testing market is categorized as Application 1, Application 2, Application 3, Application 4, Application 5. The Mitochondrial Disorders Genetic Testing market study examines the market based on key geographies such as Asia Pacific,North America, The Middle East and Africa, Europe, and Latin America.

To Get Customisation On Report Feel Free To Ask Our Experts:http://www.marketresearchstore.com/report/global-mitochondrial-disorders-genetic-testing-industry-market-2019-684945#InquiryForBuying

The present study also provides competitive analysis in terms of various parameters such as direct competition, indirect competition, strength and weaknesses of major competitors, entry barriers, and opportunity windows. The market study by application includes the analysis on the availability of total customer base and the potential customers across untapped markets. For value chain investigation of the Mitochondrial Disorders Genetic Testing market covers upstream suppliers of raw materials, equipment, downstream marketing channels, client survey, and buyers segments. Market proposals and development trends, which more precisely contain valuable facts and statistics on Mitochondrial Disorders Genetic Testing key types and applications, key market regions and consumption level, key worldwide distributors , contact information for these upstream and downstream participants.

Competitive Analysis

It includes detailed summaries of leading market performers, unique business model analysis, and examination of their latest developments. The data is extract edover primary interviews withtop business executives in addition to analysis of company published annual reports. The market study also delivers a wide-ranging analysis of key tactics employed by major Mitochondrial Disorders Genetic Testing companies and their financial investigation for different geographical regions.

Please Visit the Mitochondrial Disorders Genetic Testing Market Report at:http://www.marketresearchstore.com/report/global-mitochondrial-disorders-genetic-testing-industry-market-2019-684945

Important Take aways of Research Report:

1. Market Value and Volume Size for Historical and Forecast Period2. Market Growth Trends for Forecast Period3. Y-O-Y ( Year On Year) Growth Rate for Various Market Segments4. Market Entry Barriers, Opportunities, Possible Threats, and Alternatives5. Qualitative Market Analysis through various tools such as Porters Five Forces Model,SWOT Analysis,and PESTLE Analysis

View original post here:
Global Mitochondrial Disorders Genetic Testing Market with Coronavirus (Covid-19) Effect Analysis | likewise Industry is Booming Globaly with Key...